Stock Code：4188

安克生醫股份有限公司
AmCad BioMed Corporation

Handbook for the 2025 Annual Meeting of Shareholders

Form of meeting：Physical Meeting

Meeting Time：June 3, 2025

Meeting Place：3rd Fl., No.10 Shih-er Rd.,Yangmei District, Taoyuan City

Table of Contents

I.Meeting Procedures **1**

II.Meeting Agenda **2**

A.Report Items 3

B.Acknowledged Matters 4

C.Discussion Matters 6

D.Extemporary Motions 11

E. Adjournment 11

III. Attachments

A.The 2024 Business report 12

B.The 2024 Audit Committee’s Review Report 15

C.Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and the Underwriter’s Evaluation Results on the Reasonableness of Each Expenditure 16

D.2024 Independent Auditors’ Report and Financial Statements 31

E.Articles of Incorporation Comparison Table for the Amended Provisions 51

IV. Appendix

A.Rules of Procedure for Shareholders’ Meetings 54

B.Articles of Incorporation 63

C.Shareholding Status of Directors 70

I. Meeting Procedures

AmCad BioMed Corporation
Procedure for the 2025 Annual Meeting of Shareholders

A. Calling the Meeting to Order (Report the total number of shares present)

B. Chairperson Remarks

C. Report Items

D. Acknowledged Matters

E. Discussion Matters

F. Extemporary Motions

G. Adjournment

II. Meeting Agenda

AmCad BioMed Corporation
Procedure for the 2025 Annual Meeting Agendas

Form of meeting：Physical Meeting

Meeting Time：9:00a.m., Tuesday , June 3, 2025

Meeting Place：3rd Fl., No.10 Shih-er Rd., Yangmei District, Taoyuan City

A. Call the Meeting to Order (Report the total number of shares present)

B. Chairperson Remarks

C. Report Items

1. The 2024 Business Report.
2. The 2024 Audit Committee’s Review Report.
3. Report on the Execution Status of the Private Placement of Common Shares Approved at the 2024 Annual General Shareholders’ Meeting.
4. Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and Evaluation Results on the Reasonableness of Each Expenditure Item as Assessed by the Underwriter.

D. Acknowledged Matters

1. Adoption of 2024 the Financial Statements and Business Report.
2. Adoption of the Proposal for 2024 Deficit Compensation.

E. Discussion Matters

1. Discussion on the Proposal for Private Placement of Common Shares through Cash Capital Increase.
2. Amendment to the "Articles of Incorporation".

F. Extemporary Motions

G. Adjournment

A. Report Items

1. The 2024 Business Report.

   Explanation：Please refer to Attachment A (pages 12~14) for detailed Business Reports.

2. The 2024 Audit Committee's Review Report.

   Explanation：Please refer to Attachment B (page 15) for 2024 Audit Committee's ReviewReport.

3. Report on the Implementation Status of the Private Placement of Common Shares Approved at the 2024 Annual General Shareholders' Meeting.

   Explanation：a. On June 26, 2024, the Company's shareholders approved a resolution at the Annual General Shareholders' Meeting to conduct a private placement of common shares through cash capital increase. Pursuant to Article 43-6 of the Securities and Exchange Act, privately placed securities must be executed within one year from the date of the shareholders' resolution.

   b.As the one-year period is approaching expiration, the private placement will not proceed.

4. Report on the Implementation Status of the Sound Business Operation Plan, the Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases, Actual Use of Funds, and the Underwriter's Evaluation Results on the Reasonableness of Each Expenditure Item.

   Explanation：For details on the Company's implementation status of the sound business operation plan, the progress of fund utilization from the 2015 and 2024 cash capital increases, actual use of funds, and the underwriter's evaluation results on the reasonableness of each expenditure item, please refer to Attachment C (pages 16～30) of this handbook for your review.

B. Acknowledged Matters

Proposal 1

Proposal：Adoption of 2024 the Financial Statements and Business Report.

(Proposed by the Board of Directors)

Explanation：a. The Company’s 2024 Financial Statements and Business Report were approved by the Audit Committee and resolved by the Board of Directors on February 25, 2025. The financial statements were audited and certified by Ernst & Young Accountants Muriel Yu and Joy Chang, and issued "Unqualified Opinion".

b. Please refer to Attachment A (page 12~14) for detailed Business Reports and Attachment D (page 31~50) for Financial Statements.

c. Please acknowledge.

Resolution：

Proposal 2

Proposal：Adoption of the Proposal for 2024 Deficit Compensation.

(Proposed by the Board of Directors)

Explanation：a. The Company’s beginning accumulated deficit was NT$148,742,658. After deducting the net loss after tax of NT$50,577,530 for the year 2024, the ending accumulated deficit amounts to NT$199,320,188.

b. This case has been approved by the Audit Committee and the Board of Directors on February 25, 2025.

c. Please refer to 2024 Deficit Compensation as follows：

Unit: NT$

Item	Amount
Losses to be made up at the beginning of the period	(148,742,658)
Less：Net loss after tax in 2024	(50,577,530)
Losses to be made up at the end of the period	(199,320,188)

Chairman：Lee Yi-Li

General Manager：Lee Yi-Li

Accounting supervisor：Ann Chen

d. Please acknowledge.

Resolution：

C. Discussion Matters

Proposal 1

Proposal：Proposal for Private Placement of Common Shares through Cash Capital Increase.

(Proposed by the Board of Directors)

Explanation：a. To accelerate product promotion and enhance the Company's revenue and profitability, it is proposed to conduct a private placement of common shares within a limit of no more than 15,000,000 shares.

b. Pursuant to Article 43-6 of the Securities and Exchange Act and the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the following matters regarding the private placement of common shares are hereby explained：

(1)Basis and Reasonableness of Pricing：

(i)The price per share for the private placement shall not be lower than 80% of the reference price. The reference price shall be the higher of the following two averages.

1-1 The simple arithmetic average of the closing prices of the Company's common shares for either 1, 3, or 5 business days prior to the pricing date, adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

1-2 The simple arithmetic average of the closing prices of the Company's common shares for the 30 business days prior to the pricing date, also adjusted for any ex-dividend and ex-rights effects, and reinstated for any capital reduction.

The actual pricing date and private placement price will be determined by the Board of Directors, within the authorized range approved by the shareholders' meeting, based on negotiations with specific investors in the future.

(ii)In addition to complying with the relevant provisions of the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the pricing rationale also considers that privately placed securities shall be subject to a three-year transfer restriction starting from the delivery date. Moreover, within this period, the securities may not be registered for public issuance or listed on the stock exchange. Therefore, the pricing is deemed reasonable.

(2)Method of Selecting Specific Investors：

(i) The private placement targets shall be limited to specific investors as defined in Article 43-6 of the Securities and Exchange Act and in accordance with the Financial Supervisory Commission's directive No. 1120383220 dated September 12, 2023.

(ii) The Company has not yet confirmed any subscribers for the private placement. However, if the subscribers are insiders or related parties, their selection method, purpose of participation, and relationship with the Company will be explained as follows：

Subscriber(s)	Selection Method and Purpose	Relationship with the Company
Phytohealth Corp.	To ensure the long-term stability of the Company's operations	Parent Company
Maywufa Company Limited.	To ensure the long-term stability of the Company's operations	Affiliates

Disclosure Requirements if the Subscriber is a Corporate Entity：

Corporate Subscriber	The names and shareholding percentages of its top ten shareholders		Relationship with the Company
	Name	Shareholding Percentage	
Phytohealth Corp. (As recorded in the shareholders' register as of April 6, 2025)	Maywufa Company Ltd. Representative：Lee Chen-Chia	17.69% 0.15%	Corporate Director Director
	Yun Cheng Investment Corporation	0.90%	NA
	Chen Qing-Tang	0.60%	NA
	Zheng An-Hang	0.58%	NA
	Wu Yu-Kun	0.53%	NA
	Wu Li-Hua	0.51%	NA
	Wu Zhao-Xiong	0.50%	NA
	Chang Te-Rong	0.48%	NA
	Lu Xue-Chang	0.48%	NA
	National Defense Education Foundation Research Foundation	0.48%	NA
Maywufa Company Limited. (As recorded in the shareholders' register as of April 7, 2025)	Cheng Yi Investment Company Ltd. Representative：Lee Chen-Chia	17.75% 2.03%	NA Director
	Phytohealth Corp. Representative：Lee Yi-Li	12.59% 1.05%	Corporate Director Chairperson and CEO
	Li Ling Investment Company Ltd. Representative：Lee Chen-Chia	11.25% 2.03%	NA Director
	Chen Wen-Hwa	2.71%	NA
	Cheng Hsin Investment Company Ltd.	2.36% 2.03%	NA Director

	Representative：Lee Chen-Chia		
	Lee Chen-Chia	2.03%	Director
	Lee Yi-Li	1.05%	Chairperson and CEO
	Yi Xin International Company Ltd.	1.04%	NA
	Representative：Lee Yu-Chia	0.08%	NA
	Tsai Mao-Chen	1.03%	NA
	Lin Ting-Chi	0.81%	NA

(3)Necessity of Conducting a Private Placement：

(i) Reason for Not Using a Public Offering：Taking into account the conditions of the capital market, timeliness, convenience, and cost-effectiveness of capital raising, the Company proposes to raise funds through a private placement at an appropriate time with specific investors. This approach is intended to facilitate a prompt injection of required capital.

(ii)Private Placement Quota：The total number of shares to be privately placed shall not exceed 15,000,000 shares and shall be executed in one tranche within one year from the date of the shareholders' resolution.

(iii)Purpose of Funds and Expected Benefits：

Proposed Number of Shares to Be Privately Placed	Use of Proceeds	Expected Benefits
15,000,000	1. To strengthen working capital – Ensuring stable operations and financial flexibility for the Company's ongoing activities. 2. To continue investment in new product development and related clinical trials – Supporting innovation, regulatory approvals, and future revenue growth. 3. To develop new markets – Expanding the Company's international presence and accelerating market penetration.	To accelerate the promotion of the Company's products in domestic and international markets, thereby increasing revenue and profitability.

c. The rights and obligations of the common shares to be privately placed under this proposal shall, in principle, be the same as those of the Company's existing common shares. However, except for the transferees permitted under Article 43-8 of the Securities and Exchange Act, the privately placed common shares shall not be transferred within three years from the delivery date. After the three-year restriction period, the Company may apply to the competent authority for

retroactive public issuance and listing, provided that all relevant regulatory requirements are met.

d. The key terms of this private placement—including but not limited to the issuance price, number of shares, total proceeds, project plans, expected timeline for fund utilization, anticipated benefits, and other related matters—shall be determined by the Board of Directors based on market conditions and the Company's operational needs, as authorized by the shareholders' meeting. Should any changes be necessary due to amendments by the competent authority, operational assessments, changes in the external environment, or legal requirements, the Board of Directors is hereby fully authorized to make the necessary adjustments.

e. It is proposed that the Chairperson or his/her designated representative be authorized to act on behalf of the Company in signing and negotiating all agreements and documents related to this private placement and to take all necessary actions in connection therewith.

f. This proposal has been approved by the Audit Committee and resolved by the Board of Directors on February 25, 2025.

g. Your discussion is respectfully requested.

Resolution：

Proposal 2

Proposal：Proposal to Amend the Articles of Incorporation

(Proposed by the Board of Directors)

Explanation：a.In accordance with Article 14 of the Securities and Exchange Act, companies whose shares are traded over-the-counter (OTC) are required to include provisions in their Articles of Incorporation regarding the allocation of a certain percentage of annual earnings to adjust compensation or distribute remuneration to grassroots employees, as well as the adjustment of dividend policies. To comply with these requirements, the Company proposes to amend certain provisions of its Articles of Incorporation.

b.Please refer to Attachments E (pages 51~53) of this handbook for the comparison table of the current and amended Articles.

c.This proposal was approved by the Board of Directors on February 25, 2025.

d.Your discussion is respectfully requested.

Resolution：

D. Extemporary Motions

E. Adjournment

III. Attachments

Attachment A

AmCad BioMed Corporation
The 2024 Business Report

1. Business Strategy and Implementation Overview

In 2024, the global healthcare market continued to recover, and the application of AI in medical imaging diagnostics became increasingly mature. AmCAD-UO® maintained stable growth in Taiwan. Following the approval of self-pay coding in Taichung, the Company also obtained similar approvals from the Taipei City and New Taipei City Departments of Health, further expanding clinical adoption and market penetration. The Company entered into collaborative research agreements with the School of Dentistry at the University of the Pacific and Stanford University in the United States to explore applications in dental care. In addition, the Company signed a procurement agreement with a premium AI diabetes care clinic in Dubai to promote product application in weight-loss therapy. A clinical study conducted at the University of Bern in Switzerland was successfully completed and will be submitted to an international journal, further enhancing the Company's global academic recognition and product credibility.

AmCAD-UT® successfully entered several medical institutions in 2024, including China Medical University Hsinchu Hospital and Tainan Hospital under the Ministry of Health and Welfare. It is now adopted by more than 30 hospitals across Taiwan. It has also been included in the list of proposed items for National Health Insurance (NHI) coverage and is expected to receive reimbursement approval in 2025, marking a major milestone in the Company's development of innovative medical devices.

As a leading AI medical device innovator in Taiwan, Anker Biomedical possesses advanced AI technologies and a robust patent portfolio. Looking forward, the Company will continue enhancing its AI diagnostic capabilities, promoting the application of AmCAD-UT®, AmCAD-UO®, and AmCAD-UB® across various medical fields. Through co-development discussions with leading ultrasound manufacturers, the Company aims to deepen international collaboration and integrate real-time AI-assisted imaging with handheld ultrasound devices to improve accessibility and accelerate global market entry.

2. Implementation Results of Business Plan and Budget Execution

The major operational achievements for 2024 are outlined below by product：

a. AmCAD-UT®

(1) Successfully entered China Medical University Hsinchu Hospital, Tainan Hospital under the Ministry of Health and Welfare, and other medical institutions.

(2) Submitted for inclusion in the NHI reimbursement list in the first half of 2024; temporary reimbursement approval expected in 2025 to enhance market adoption.

(3) Signed a Memorandum of Understanding (MOU) with Dubai-based Meridian Healthcare (MHC) to initiate Middle East market collaboration.

(4) Continued optimization of deep learning algorithms for UT, improving diagnostic accuracy and developing automatic scan plane detection functions.

(5) Developed UT LiveScan to enhance real-time scanning guidance and seize point-of-care ultrasound (POCUS) market opportunities.

b. AmCAD-UO®

(1) Partnered with Sunshine Clinic on corporate screening programs and combined product sales for a successful new business model.

(2) Collaborated with the University of the Pacific and Stanford University to expand product applications in dentistry and conducted ongoing post-market clinical studies.

(3) Signed a procurement agreement with a high-end AI diabetes clinic in Dubai to promote the product's use in weight-loss therapy.

(4) Swiss clinical research confirmed that AmCAD-UO®'s backscatter technology improves the success rate of HNS therapy; the study was presented at an international conference and submitted to a peer-reviewed journal.

(5) Continued clinical collaborations with NTU Hospital, Chang Gung Memorial Hospital, and Tzu Chi Hospital to increase clinical value of the product.

3. Budget Execution

In accordance with the "Regulations Governing the Publication of Financial Forecasts by Public Companies," the Company did not publish a financial forecast for 2024. Therefore, this section is not applicable.

4. Financial Expenditures and Profitability Analysis

Unit: NT$ thousand

Project \ Year		2024	2023	Increase (decrease)%
Finance revenue and expenditure	Operating revenue	53,105	65,256	(19)
	Gross profit	32,934	41,024	(20)
	Net Operating loss	(64,664)	(53,985)	-
	Net non-operating income and expenses	11,788	10,836	9
	Net loss after tax	(52,876)	(43,149)	-
Profitability	Return on assets (%)	(8.73)	(8.07)	-
	Return on equity (%)	(9.26)	(8.65)	-
	Profit rate (%)	(99.57)	(66.12)	-
	Loss per share (in NT$)	(0.88)	(0.85)	-

5. Research Development Status

a. 2024 annual research and development expenditure

Project \ Year	2024
Operating revenue (A)	53,105(in thousands)
Research and development expenses (B)	43,783(in thousands)
Total number of employees (C)	76 people

Total R&D personnel (D)	19 people
R&D expenditure ratio B/A	82%
R&D manpower to total manpower D/C	25%

b. 2024 annual research and development results

(1)AmCAD-UT®

– Optimized the AI deep learning model to enhance diagnostic accuracy.

– Developed Android and iOS versions with integrated AI detection features.

– Released the UT LiveScan version, compatible with multiple ultrasound systems.

(2)AmCAD-UO®

– Continued development of customized reporting features.

– Enhanced deep learning and diagnostic models.

– Published clinical study results from the University of Bern, Switzerland, validating product efficacy.

– Ongoing clinical data collection and analysis with NTU Dental School, Chang Gung Memorial Hospital, and pediatric departments.

(3)AmCAD-US (Ultrasound Scatter Imaging Platform)

– Focused on software optimization and cybersecurity enhancement.

(4)AmCAD-UB®

– Developed Android version with integrated AI detection capabilities.

– Launched UB Live functionality with ultrasound system integration.

– Conducted clinical consultation with physicians for feedback and validation.

(5)Regulatory Affairs and Patents

– Obtained KFDA certification for the S1000 system.

– Passed QMS (Quality Management System) certification.

– Completed TFDA site change and certificate extension for UT and UO systems.

– Achieved zero non-conformities in SGS audit for QMS and ISO 13485 documentation across all product lines.

– Ongoing office action responses and arguments for UO patents in the United States, Taiwan, and Europe.

Chairman：Lee Yi-Li

General Manager：Lee Yi-Li

Accounting Supervisor：Ann Chen

Attachment B

AmCad BioMed Corporation
Audit Committee's Review Report

We have agreed and submitted the Company's 2023 financial statements to the board of directors and obtained the approval of the board of directors. The financial statements have been audited by Ernst & Young Taiwan engaged by the board of directors with an unqualified opinion in the independent auditor's report.

We audited the Company's 2023 business report and deficit compensation proposal which have been resolved by the board of directors and has concluded that both of them are in accordance with the related regulations. Pursuant to the regulations set forth in Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act, a report is submitted as above. Please review.

Sincerely,

AmCad BioMed Corporation 2025 Annual General Meeting of Shareholders

Convener Of Audit Committee：Chang Ching-Tian

February 25, 2025

Attachment C

AmCad BioMed Corporation

Implementation Status of the Sound Business Operation Plan; Progress of Fund Utilization from the 2015 and 2024 Cash Capital Increases; Actual Use of Funds; and the Underwriter's Evaluation Results on the Reasonableness of Each Expenditure

Explanation：

1. In accordance with the letters issued by the Financial Supervisory Commission (FSC) and Taipei Exchange (TPEx), including FSC Letter No. 1020040686 dated October 8, 2013, TPEx Letter No. 1040002972 dated February 13, 2015, FSC Letter No. 105004713 dated March 14, 2016, FSC Letter No. 1060026943 dated July 20, 2017, and FSC Letter No. 1130343354 dated June 7, 2024.

2. Progress of the Sound Business Operation Plan Execution：

   a. Product Development and Business Promotion

      (1) AmCAD-UT® (Thyroid Ultrasound Computer-Aided Detection System)

      This product has obtained regulatory approvals including U.S. FDA 510(k), EU CE, Taiwan TFDA, and China CFDA. International market expansion is ongoing, with operations launched in the EU and Middle East, and adoption by premium clinics in Dubai. Domestically, the Company continues to promote a subscription-based sales model while conducting product implementation and feedback collection in clinical settings. Inclusion in the National Health Insurance reimbursement scheme is expected in the second half of this year.

      (2) AmCAD-UO® (Ultrasound Obstructive Sleep Apnea Detection System)

      The product has obtained approvals from the U.S. FDA 510(k), EU CE, and Taiwan TFDA.Domestically, in addition to existing self-pay reimbursement codes in Taipei City and New Taipei City, a new self-pay code was obtained in Chiayi City in Q1 2025 (self-pay amount: NT$4,000). Clinical research collaborations with medical institutions are ongoing to expand clinical applications and market penetration.Internationally, the product has been adopted by premium clinics in Dubai. Research collaboration with the University of the Pacific School of Dentistry in the U.S. is ongoing. In addition, clinical study results from Switzerland were successfully published in the internationally renowned journal OTO-HNS, further enhancing the product's global academic visibility.

      (3) AmCAD-CA® (Thyroid Cytology Assessment System)

      This system assists physicians in performing fine-needle aspiration cytology (FNAC) to enhance diagnostic efficiency and accuracy. It will be integrated with the AmCAD-UT® system to strengthen the overall diagnostic workflow and technological synergy.AmCAD-Color Enhancement

      (4) Development of Diagnostic Hardware for Obstructive Sleep Apnea (OSA)

      This project builds on the clinical experience of the first-generation AmCAD-UO to develop a next-generation diagnostic hardware system for OSA. The new system incorporates laser

alignment technology to enhance the precision of oral and upper airway structure scanning and expands its application to pediatric populations. In Q1 2025, optimization of the Head & Neck Laser Alignment Tool continued, and a deep learning computing system was introduced to improve model performance and AI analysis capabilities.

(5) Breast Ultrasound AI Diagnostic System

This product integrates AI-based real-time image interpretation technology to perform intelligent analysis of breast ultrasound images. In Q1 2025, development focused on a high-sensitivity AI module for preliminary screening, ensuring hardware compatibility and clinical workflow integration. The UB Live scanning interface, feature extraction algorithms, and automated reporting module were completed. The product has been made available for clinical trials at both domestic and international medical institutions, with user feedback being collected continuously to further enhance system functionality.

(6) Handheld Ultrasound Device Development

To expand the application of AI technology in lightweight diagnostic equipment, device testing and physician evaluations were conducted in Q1 2025. The Company is actively exploring collaboration models with leading international manufacturers and engaging with potential partners to enhance technological integration, strengthen brand positioning, and improve the product's market competitiveness.

b. Revenue and Profitability Performance

Some projects funded through capital increases are still in the research and clinical validation stages and have not yet been fully converted into revenue, resulting in deferred financial outcomes. The Company will continue to advance product commercialization and market introduction. As products enter clinical application and obtain health insurance coverage, revenue and profitability performance are expected to gradually materialize.

3. Progress Report and Evaluation on the Use of Proceeds from the 2015 First and Second Cash Capital Increases and the 2024 Cash Capital Increase, Including Actual Disbursements and Reasonableness Assessment by the Underwriter：

a. The First Cash Capital Increase in 2015 was approved by the Taipei Exchange via Letter No. 1040002972 dated February 13, 2015. The total planned funding amount was NT$182.4 million, and all proceeds were fully utilized by the end of fiscal year 2019.

b. The Second Cash Capital Increase in 2015 (hereinafter referred to as "the Case") was approved by the Financial Supervisory Commission on March 14, 2016, via Letter No. 1050004713. The proceeds raised under this Case were designated for product development projects (hereinafter referred to as "the Project"), with a total planned budget of NT$267.001 million.
Subsequently, the Board of Directors approved a project modification on November 6, 2018, and a further revision on August 9, 2022. The Company has provided an evaluation report addressing：

- the implementation progress before and after the revisions,

- the expected achievement of project benefits, and
- the reasonableness of the use of remaining funds.

(1)Original Project Scope, Schedule, and Expected Benefits

(i) Original Project Scope

1-1 Total Capital Requirement: NT$267,001 thousand.

1-2 Sources of Funds：

(a) The Company planned to raise capital through a cash capital increase by issuing 11,800 thousand common shares, each with a par value of NT$10, at an issue price of NT$30 per share. The total expected proceeds were NT$354,000 thousand.

(b) If the actual issue price per share was adjusted due to market price fluctuations, resulting in a higher fundraising amount, the excess would be allocated to working capital.

1-3 Original Capital Deployment Plan

Unit: NT$ thousand

Project Item		Planned Completion Date	Total Required Capital	Planned Fund Utilization Schedule									
				2016				2017				2018	
				Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	61,475	3,140	5,471	2,261	9,107	6,286	6,627	4,629	8,806	6,490	8,658
	Smart Functional Ultrasound Device	2018Q2	205,526	2,842	31,596	2,342	11,956	29,340	6,378	32,409	23,170	35,248	30,245
	Reinforcement of Working Capital	2016Q2	86,999	-	86,999	-	-	-	-	-	-	-	-
	Total		354,000	5,982	124,066	4,603	21,063	35,626	13,005	37,038	31,976	41,738	38,903

(ii)Original Planned Schedule for Fund Utilization

Unit: NT$ thousand

Project Item	Execution Status		Cumulative as of Q3 2018
Cytology-Based Thyroid Tumor Identification System	Amount Utilized	Planned	61,475
		Actual	27,290
	Execution Progress(%)	Planned	100.00
		Actual	44.39
Smart Functional Ultrasound Device	Amount Utilized	Planned	205,526
		Actual	28,335
	Execution Progress(%)	Planned	100.00
		Actual	13.79
Reinforcement of Working Capital	Amount Utilized	Planned	86,999
		Actual	86,999
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Total	Amount Utilized	Planned	354,000
		Actual	142,624
	Execution Progress(%)	Planned	100.00
		Actual	40.29

Source: Provided by the Company.

The fund utilization progress of the company's second cash capital increase in 2015 fell behind schedule. This delay was primarily due to the fundraising being completed later than originally planned—on June 27, 2016—which resulted in postponed procurement of certain hardware equipment. In addition, discussions with academic institutions and partner manufacturers regarding technical development and integration details led to deferred payments. As of the third quarter of 2018, the accumulated amount utilized was NT$142,624 thousand, representing 40.29% of the originally planned execution progress. Upon evaluation, no material irregularities were identified.

(iii)Status of Achievement of Originally Planned Expected Benefits

The total amount of this capital increase plan is NT$354,000 thousand, of which NT$267,001 thousand is allocated for product development. The main purpose is to develop two new products: a Cytology-based Thyroid Tumor Identification System and a Smart Functional Ultrasound Device, with planned investments of NT$61,475 thousand and NT$205,526 thousand, respectively.

The development of the Cytology-based Thyroid Tumor Identification System aims to assist physicians in improving the diagnostic accuracy of benign and malignant tumors in traditional fine-needle aspiration cytology by providing image-based markers through software. The development was scheduled for completion in the first half of 2018, with a subsequent application for U.S. FDA marketing approval. It is projected to generate revenue of NT$7,300 thousand in the second quarter of 2020.

The Smart Functional Ultrasound Device is designed to address the limitations of current ultrasound systems, which lack real-time image analysis and anomaly alerts. This product integrates the company’s medical imaging and CAD software development capabilities and is jointly developed with ultrasound hardware manufacturers. Development was also scheduled for completion in the first half of 2018, followed by an application for U.S. FDA approval. Revenue of NT$100,800 thousand is expected to be generated in the second quarter of 2020.

The projected development timeline and the estimated benefits from future sales of the company’s products are summarized as follows：

1-1Planned Product Development Timeline

Product	Design Planning	Design Input	Design Output	Design Verification	Preclinical Evaluation	Marketing Approval Application
Cytology-Based Thyroid Tumor Identification System	2015Q2	2016Q1	2016Q4	2017Q2	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application
Smart Functional Ultrasound	2015Q2	2016Q2	2017Q1	2017Q3	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application

Source: Provided by the Company.

1-2Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System

Unit: Units; NT$ Thousands

Year	Sales Volume		Unit Price		Sales Value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2020	19	7	200	500	3,800	3,500	6,644	(20,544)
2021	102	23	200	500	20,400	11,500	29,033	9,017
2022	127	37	200	500	25,400	18,500	39,955	24,583
2023	153	51	200	500	30,600	25,500	51,059	37,209
2024	178	66	200	500	35,600	33,000	62,435	49,161

Source: Provided by the Company.

1-3Expected Potential Benefits of the Smart Functional Ultrasound Device

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2020	42	2,400	100,800	60,726	(851)
2021	118	2,400	283,200	170,611	116,163
2022	186	2,400	446,400	268,929	216,746

Source: Provided by the Company.

As of the end of the third quarter of 2018, the product development projects had not yet been completed; therefore, it is not yet necessary to assess the achievement of the projected sales revenue for the Cytology-Based Thyroid Tumor Identification System and the Smart Functional Ultrasound Device.

(2) Capital Plan, Execution Progress, and Expected Benefits Following the Project Amendment Approved by the Board of Directors on August 9, 2022.

(i) Reason for the Project Amendment

Revision of Product Development Items

As of July 2022 (Year 111), the development of the Cytology-Based Identification System had been completed. In order to efficiently utilize the remaining funds, the company proposed reallocating the unused portion originally designated for the Cytology-Based Identification System to support the ongoing product development of the Smart Functional Ultrasound Device.

1-1 Since the purpose of developing the Cytology-Based Identification System is to complement the Anke Thyroid Detection product and assist physicians in diagnosing thyroid conditions, the market strategy is to distribute it in conjunction with the Anke Thyroid Detection system through laboratory channels. Therefore, FDA approval is not required.

1-2 The product development of the Smart Functional Ultrasound Device aims to effectively enhance product value. In addition to its existing rapid diagnostic function for sleep apnea, the device is also being developed for broader applications in companion diagnostics (such as positive airway pressure devices, oral appliances, and surgical resection). The company is currently collaborating with major hospitals and research centers to conduct related clinical validation studies.

(ii) Revised Project Items and Fund Utilization Progress

Unit: NT$ Thousands

Project Item		Planned Completion Date	Total Required Capital	Actual Fund Utilization Progress						Planned Fund Utilization Progress											
				2016	2017	2018	2019	2020	2021	2022				2023				2024			
										Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	38,681	7,039	10,256	12,565	5,954	952	1,151	313	334	117 (註 2)	-	-	-	-	-	-	-	-	-
	Smart Functional Ultrasound Device	2018Q2	158,562	13,756	13,158	1,421	-	12,596	21,680	4,414	4,764	7,826	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503
Reinforcement of Working Capital		2016Q2	86,999	86,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Office Building Purchase		2018Q4	61,083	-	-	61,083 (註 1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity Investment in Subsidiaries		2018Q4	27,000	-	-	27,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Amount			372,325	107,794	23,414	102,069	5,954	13,548	22,831	4,727	5,098	7,943	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503

Note 1：Of the total, NT$18,325 thousand was funded with the company's own capital, while the remaining NT$42,758 thousand was covered by the original budget allocated for the product development of the Smart Functional Ultrasound Device.

Note 2：The Cytology-Based Thyroid Tumor Identification System was completed in July 2022.

(iii)Fund Utilization Progress After Project Amendment

Unit: NT$ Thousands

Project Item	Execution Status		Cumulative as of Q1 2025
Cytology-Based Thyroid Tumor Identification System	Amount Utilized	Planned	38,681
		Actual	38,681
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Smart Functional Ultrasound Device	Amount Utilized	Planned	158,562
		Actual	148,398
	Execution Progress(%)	Planned	100.00
		Actual	93.59
Office Building Purchase	Amount Utilized	Planned	61,083
		Actual	61,083
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Equity Investment in Subsidiaries	Amount Utilized	Planned	27,000
		Actual	27,000
	Execution Progress(%)	Planned	100.00
		Actual	100.00
Total	Amount Utilized	Planned	285,326
		Actual	275,162
	Execution Progress(%)	Planned	100.00
		Actual	96.44

Source: Provided by the Company.

The fund utilization progress of the company's second cash capital increase in 2015 is as follows: the product development of the Cytology-Based Thyroid Tumor Identification System, the purchase of office buildings, and the equity investment in subsidiaries have all been completed. However, as of the first quarter of 2025, the development of the Smart Functional Ultrasound Device has experienced delays.

The delay is mainly attributed to intensified competition in the target application market of the end product, which led hardware manufacturers to propose integrating various CAD software technologies with hardware devices. Additionally, during the pandemic, certain FDA application processes for CAD software were delayed due to slower case acceptance, which further hindered development progress.

Nonetheless, as of the date of this evaluation, the company has completed the development of the Smart Functional Ultrasound Device and has secured sales orders. The company also plans to continue investing in related R&D efforts to further enhance the functionality of the product.

Overall, the accumulated fund utilization under this plan reached NT$275,162 thousand as of the first quarter of 2025, representing an actual execution rate of 96.44%. The delay is primarily due to adjustments made in response to external market conditions, and no material irregularities have been identified upon evaluation.

(iv)Expected Benefits After the Amendment

1-1 Product Development

(a) Planned Product Development Timeline

Product	Design Verification	Clinical Enrollment	Publication	Marketing

Smart Functional Ultrasound	Ongoing Function Optimization	OSA Evaluation / Companion Therapy Enrollment Ongoing	In Progress	FDA Application for Sleep Apnea Assessment Completed in 2024

Note: Due to the limited market potential of the MSK project, the company shifted its focus to the OSA (Obstructive Sleep Apnea) diagnostic field, in which it has already achieved notable results. Considering the business opportunities associated with companion therapies, the company is continuing with related clinical case collection.

(b) Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System

Unit: Sets; NT$ Thousands

Year	Sales Volume		Unit Price		Sales Value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2023	8	3	100	250	800	750	1,488	37
2024	19	8	100	250	1,900	2,000	3,769	2,562
2025	31	11	100	250	3,100	2,750	5,687	3,981
2026	45	17	100	250	4,500	4,250	8,491	6,243
2027	47	19	100	250	4,700	4,750	9,159	6,353
2028	50	22	100	250	5,000	5,550	10,218	7,094

Source: Provided by the Company.

(c) Expected Potential Benefits of the Smart Functional Ultrasound Device

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2023	10	2,000	20,000	12,510	5,417
2024	23	2,400	55,200	38,788	26,096
2025	40	2,400	96,000	69,405	48,363
2026	48	2,400	115,200	84,093	58,491

Source: Provided by the Company.

1-2 Purchase of Office Building

Following the approval of the project amendment by the Board of Directors on November 6, 2018, the company purchased an office unit on the third floor of the same building as the AmCad Biomed Corp. office on Fuxing North Road for NT$61,083 thousand on December 6. The total area of the purchased office is approximately 77.32 pings. Based on the market rental rate of approximately NT$1,800 per ping per month—referencing the rental income received by PhytoHealth Corp., the parent company of AmCad Biomed Corp., for the eighth floor of the same building—it is estimated that the company can save approximately NT$1,670 thousand in annual rental expenses.

After deducting the estimated annual depreciation expense of NT$204 thousand associated with the acquired office property, the net annual benefit starting from 2019 is projected to be approximately NT$1,466 thousand. This benefit is in line with expectations.

Unit: Units; NT$ Thousands

	From 2019 Onward
Expected Annual Rent Savings (Note 1)	1,670
Building Depreciation Cost (Note 2)	(204)
Total	1,466

Source: Provided by the Company.

Note 1：The estimated annual rental savings are calculated based on the prevailing rental rates in the intended purchase area and the planned office space area.

Note 2：The total purchase price of the property (including transfer and related acquisition costs) is estimated at NT$8,142 thousand. Based on a 40-year amortization schedule, the annual depreciation amount is NT$204 thousand (NT$8,142 thousand ÷ 40 years).

1-3 Equity Investment in Subsidiaries

Unit: Units; NT$ Thousands

	2018	2019	2020	2021	2022
Operating Revenue	49,000	119,640	161,430	204,870	250,470
Gross Profit	24,850	69,358	93,183	118,407	144,927
Operating Profit	11,314	21,058	42,783	62,607	83,727
Net Income for the Period	11,314	21,058	34,226	50,086	66,982
Investment Ratio	40.54%	40.00%	40.00%	40.00%	40.00%
Recognized Investment Income for the Year	4,587	8,423	13,690	20,034	26,793
Cumulative Recognized Investment Income	4,587	13,010	26,700	46,734	73,527
Estimated Payback Period	3.01Years				

Broadsound Corp. is a comprehensive ultrasound equipment company and the only manufacturer in the world certified for ultrasound-compatible alternative probes. The company possesses advanced and mature ultrasound technologies, and it is capable of independent research and development, design, manufacturing, global marketing, and after-sales services.

Its core product—ultrasound probes—is the only high-end alternative probe globally that has obtained both U.S. FDA marketing approval and EU CE certification. According to the projected income statement prepared by Broadsound Corp., the accumulated profit is estimated to reach NT$46,734 thousand by 2021, with a projected payback period of approximately 3.01 years.

(3) Assessment of the Variance Between Expected Benefits and Actual Results

(i) Product Development

As of the end of December 2022, the development of the Cytology-Based Thyroid Tumor Identification System had just been completed. According to the company's original plan, revenue generation was expected to begin in 2023. However, in order to better meet market demand and enhance product competitiveness, the company has

revised its strategy to integrate the Cytology-Based Thyroid Tumor Identification System with the Thyroid Detection product for joint sales. The company has initiated engagement with prominent domestic hospitals, and by 2024, it had generated revenue of NT$180 thousand.

In addition, the Smart Functional Ultrasound Device has entered into sales agreements with overseas distributors and generated NT$1,580 thousand in revenue in 2024. The variance from the originally projected benefits is primarily due to the innovative nature of the Cytology-Based Thyroid Tumor Identification System, which requires substantial clinical data and research to shift physicians' diagnostic habits. Furthermore, the Smart Functional Ultrasound Device must obtain approval from the Korean KFDA before it can be fully marketed in that region.

Despite these differences in timing and revenue realization, the evaluation found no material irregularities.

(ii)Purchase of Office Building

In 2018, the company purchased a 77.32-ping office unit in an industrial-commercial building. Based on the market rental rate of approximately NT$1,800 per ping per month—referencing the rental income received by PhytoHealth Corp., the parent company of AmCad Biomed Corp., for the eighth floor of the same building—the company is estimated to save around NT$1,670 thousand in rental expenses annually.After deducting the annual depreciation expense of NT$204 thousand related to the purchased property, the net annual benefit starting from 2019 is projected to be approximately NT$1,466 thousand. Upon evaluation, this benefit is deemed reasonable.

Unit: Units; NT$ Thousands

	From 2019 and Beyond
Expected Annual Rent Savings (Note 1)	1,670
Building Depreciation Cost (Note 2)	(204)
Total	1,466

Source: Provided by the Company.

Note 1: The estimated annual rental savings are calculated based on prevailing rental rates in the intended purchase area and the purchased floor area.

Note 2: The total purchase price of the property (including transfer and related acquisition costs) is approximately NT$8,142 thousand. Based on a 40-year amortization schedule, the annual depreciation amount is NT$204 thousand (NT$8,142 thousand ÷ 40 years).

(iii)Equity Investment in Subsidiaries

Broadsound Corp. is a comprehensive ultrasound equipment company and the only manufacturer in the world certified for ultrasound-compatible alternative probes. The company possesses advanced and mature ultrasound-related technologies and is capable of independent research and development, design, manufacturing, global marketing, and after-sales service.Its core product—ultrasound probes—is the only high-end alternative probe globally that has obtained both U.S. FDA marketing approval and EU CE certification.According to Broadsound Corp.'s self-prepared financial statements for the first quarter of 2024 (Year 113), the company reported a net loss after tax of NT$3,945 thousand, primarily due to ongoing negotiations with key customers regarding order

placements.

(4) Reasonableness of the Use of Unutilized Funds

The company has not yet fully utilized the funds allocated for product development. Upon reviewing the company's bankbooks and time deposit certificates, as of the end of March 2025, the company's cash and cash equivalents totaled NT$244,122 thousand. After deducting the unutilized funds from the 2024 capital increase amounting to NT$226,996 thousand, the remaining balance is NT$17,126 thousand, which exceeds the unutilized portion of NT$10,164 thousand under this plan.The company continues to advance and enhance its product development. Based on an evaluation of the company's fund utilization progress and the amount of unutilized funds, no material irregularities have been found. The assessment by the underwriter concludes that the situation remains reasonable, with no significant issues identified.

(5) Whether the Project Involves Any Changes

The second cash capital increase plan in 2015 was amended with approval from the Board of Directors on August 9, 2022. The main purpose of the amendment was to reallocate the unutilized funds—amounting to NT$22,794 thousand—from the completed development of the Cytology-Based Thyroid Identification System to the ongoing development of the Smart Functional Ultrasound Device.Since the reallocated amount accounts for 6.44% of the total raised funds of NT$354,000 thousand, which is below the 20% threshold, it does not constitute a material change to the plan. Nevertheless, the revised fund execution schedule, the intended use of unutilized funds, and the achievement status of expected benefits have been reviewed by the underwriter and are deemed reasonable, with no material irregularities identified.

c. The 2024 Cash Capital Increase Plan (hereinafter referred to as "the Plan") was approved and became effective pursuant to the Financial Supervisory Commission's approval dated June 7, 2024, under letter No. 1130343354. The funds raised under this Plan are designated for product development (hereinafter referred to as "the Project"), with a total budget of NT$241,680 thousand.This evaluation provides an assessment of the fund execution progress, the achievement status of the expected benefits, and the reasonableness of the use of unutilized funds.

(1) Project Overview, Progress, and Expected Benefits

(i) Project Description

1-1 Total Funding Required for the Project: NT$241,680 Thousand.

1-2 Source of Funds

The company plans to raise capital through a cash capital increase by issuing 10,000 thousand common shares, with a par value of NT$10 per share and an issue price of NT$23 per share. The total amount of funds to be raised is expected to be

NT$230,000 thousand.

1-3 Planned Use of Funds

Unit: Units; NT$ Thousands

Project Item	Planned Completion Date	Total Required Capital	Planned Fund Utilization Schedule											
			2024		2025				2026				2027	
			Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Companion Diagnostic Hardware Development for Sleep Apnea	2026Q3	99,760	-	28,920	720	28,920	720	19,520	720	720	19,520	-	-	-
Breast Ultrasound Clinical Research	2027Q2	104,000	14,157	6,757	7,407	7,407	7,531	7,407	7,407	7,407	7,531	7,407	7,057	16,525
Handheld Ultrasound Device Development	2025Q3	37,920	2,400	17,880	1,680	480	15,480	-	-	-	-	-	-	-
Total		241,680	16,557	53,557	9,807	36,807	23,731	26,927	8,127	8,127	27,051	7,407	7,057	16,525

(ii)Fund Utilization Progress

Unit: Units; NT$ Thousands

Project Item	Execution Status		Cumulative as of Q1 2025
Companion Diagnostic Hardware Development for Sleep Apnea	Amount Utilized	Planned	29,640
		Actual	1,201
	Execution Progress (%)	Planned	29.71
		Actual	1.20
Breast Ultrasound Clinical Research	Amount Utilized	Planned	28,321
		Actual	736
	Execution Progress (%)	Planned	27.23
		Actual	0.71
Handheld Ultrasound Device Development	Amount Utilized	Planned	21,960
		Actual	1,067
	Execution Progress (%)	Planned	57.91
		Actual	2.81
Total	Amount Utilized	Planned	79,921
		Actual	3,004
	Execution Progress (%)	Planned	33.07
		Actual	1.24

Source: Provided by the Company.

As of the end of the first quarter of 2025, the company had utilized a total of NT$3,004 thousand for the project, representing an overall execution rate of 1.24%, which is behind the originally planned progress of 33.07%. The delay is primarily attributed to the following factors.Sleep Apnea Companion Diagnostic Hardware Development: During actual testing, the system experienced delays in equipment response. The company is currently actively troubleshooting the issue. Once resolved, the pace of fund utilization is expected to return to the planned track. In addition, the next-generation product is being designed to expand its target user group to include pediatric patients, which requires clinical trials and data collection specific to children. The design

and planning for the hardware device are expected to be completed in the second quarter of 2025.Breast Ultrasound Clinical Research: The originally designated clinical trial institution quoted a cost significantly higher than the company's expectations. Given the limited project budget, the company decided to seek an alternative, more cost-effective institution, leading to project delays. Due to the complexity of engaging with professional clinical trial institutions, the company expects to finalize the contract and commence the trial in the second quarter of 2025.Handheld Ultrasound Device Development: Drawing reference from the collaboration between GE and PIUR Imaging, which resulted in enhanced technical capabilities and brand reputation, the company has decided to reorient its strategy. Rather than limiting development to partnerships with local equipment manufacturers (e.g., Qisda), it is now actively exploring deeper collaboration opportunities with leading international firms.Despite the delays, the project's direction remains strategically sound, and no material irregularities have been identified upon evaluation.

(iii)Expected Benefits

1-1 Development of Companion Diagnostic Hardware for Sleep Apnea

Companion Diagnostic Hardware for Sleep Apnea

The company is building on its experience with the first-generation sleep apnea detection device and software to integrate AmCAD-UO with the next-generation companion diagnostic hardware. By enhancing the laser positioning system, the new device will provide a wider angle and more precise scanning of relevant oral structures. The intended user base will be expanded to include pediatric patients, with the hardware adjustable to accommodate pediatric needs. Product design planning is scheduled for the fourth quarter of 2024, with completion of the design in the third quarter of 2026, followed by submission for U.S. FDA marketing approval in the fourth quarter of 2026. Sales are expected to commence upon obtaining FDA approval in 2027.

Total projected revenue for 2027 to 2030 is NT$352,656 thousand, with total projected operating profit of NT$171,044 thousand.

Product	Design Planning	Design Input	Design Output	Design Verification	Marketing Approval Application
Companion Diagnostic Hardware for Sleep Apnea	2024Q4	2025Q2	2025Q4	2026Q3	2026Q4

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2027	8	2,232	17,856	12,736	8,660
2028	30	2,232	66,960	47,760	32,477

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2029	50	2,232	111,600	79,600	54,128
2030	70	2,232	156,240	111,440	75,779
Total	158	2,232	352,656	251,536	171,044

Source: Provided by the Company.

1-2 Breast Ultrasound Clinical Research

The breast ultrasound software is an intelligent diagnostic system for real-time breast cancer detection, which, when paired with ultrasound hardware, enables its key feature of immediate detection. To expand product opportunities overseas, the plan includes clinical trials for FDA approval in both domestic markets and the U.S., a major market for this technology. Clinical trials are expected to be completed in the second quarter of 2027, with the U.S. FDA submission scheduled for the third quarter of 2027 .Currently, a major international ultrasound manufacturer is in discussions with the company regarding collaboration on the Anke Thyroid Detection product and has also expressed interest in the breast ultrasound software. After obtaining FDA approval in the second quarter of 2028, the company plans to partner with the international ultrasound manufacturer to integrate the breast cancer ultrasound software into their existing ultrasound devices.From 2028 to 2032, the company expects to receive a total of NT$119,700 thousand in sales royalties.

Product	R&D Progress After Capital Injection	Planned Clinical Trial	Expected Start Date	Planned Completion Date of Fund Utilization	Marketing Approval Application
Breast Ultrasound	FDA Application for Breast Ultrasound	Breast Ultrasound Clinical Trial (Note 1)	2024Q3	2027Q2	2027Q3

Note: The breast ultrasound clinical trials will be conducted in both the United States and Taiwan, with an expected enrollment of 400 subjects in Taiwan and 800 subjects in the U.S. This fundraising project is scheduled to run through the second quarter of 2027, at which time the clinical trial reports will be submitted to the respective authorities in Taiwan and the U.S. for marketing approval applications.

Unit: Units; NT$ Thousands

Year	2028	2029	2030	2031	2032	2033	Total
License Volume	24	27	30	30	30	30	171
License Unit Price	700	700	700	700	700	700	700
Sales Revenue Share	16,800	18,900	21,000	21,000	21,000	21,000	119,700

Source: Provided by the Company.

1-3 Development of Handheld Ultrasound Device

The handheld ultrasound device integrates artificial intelligence into a portable ultrasound system, enhancing user convenience as well as diagnostic accuracy and efficiency. This application is particularly beneficial for patients in remote and rural areas.Under the current project timeline, product design planning is scheduled for the

fourth quarter of 2024, with design completion expected in the third quarter of 2025. The company plans to submit an application for U.S. FDA marketing approval in the fourth quarter of 2025, and commence sales upon receiving the marketing authorization in 2026. From 2026 to 2028, the projected total revenue is NT$109,500 thousand, with a total projected operating profit of NT$44,676 thousand.

Product Development Timeline	Design Planning	Design Input	Design Output	Design Verification	Marketing Approval Application
Handheld Ultrasound Device	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4

Unit: Units; NT$ Thousands

Year	Sales Volume	Unit Price	Sales Value	Gross Profit	Operating Profit
2026	230	150	34,500	20,700	14,076
2027	240	150	36,000	21,600	14,688
2029	260	150	39,000	23,400	15,912
Total	730	450	109,500	65,700	44,676

Source: Provided by the Company.

(2)Assessment of Variance Between Expected Benefits and Actual Results

As the company has not yet completed the product development projects, it is not yet necessary to assess the achievement of projected sales revenue for the companion diagnostic hardware for sleep apnea, the handheld ultrasound device, or the breast ultrasound software revenue-sharing arrangement.

(3)Reasonableness of the Use of Unutilized Funds

The company has not yet fully utilized the funds allocated for product development. Upon reviewing the company's bankbooks and time deposit certificates, as of the end of March 2025, its cash and cash equivalents totaled NT$244,122 thousand. After deducting the unutilized balance of NT$10,164 thousand from the 2015 capital increase, the remaining balance is NT$233,958 thousand—greater than the total funds raised under the current plan (NT$230,000 thousand). Based on an evaluation of the company's fund execution progress and the amount of unutilized funds, no material irregularities have been found. The assessment by the underwriter concludes that the situation remains reasonable.

(4)Whether the Project Involves Any Changes

The company’s 2024 cash capital increase plan was duly approved and became effective pursuant to the Financial Supervisory Commission's approval dated June 7, 2024, under letter No. 1130343354. As of the date of this evaluation, no changes to the project have occurred.

Attachment D

Independent Auditors' Report Translated from Chinese

To AmCad BioMed Corporation

Opinion

We have audited the accompanying consolidated balance sheets of AmCad BioMed Corporation (the "Company") and its subsidiaries as of December 31, 2024 and 2023, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the years ended December 31, 2024 and 2023, and notes to the consolidated financial statements, including the summary of material accounting policies (together "the consolidated financial statements").

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of December 31, 2024 and 2023, and their consolidated financial performance and cash flows for the years ended December 31, 2024 and 2023, in conformity with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, Interpretations developed by the International Financial Reporting Interpretations Committee or the former Standing Interpretations Committee as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company and its subsidiaries in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China (the "Norm"), and we have fulfilled our other ethical responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of 2024 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

The Company and its subsidiaries recognized operating revenue amounts to NT$53,105 thousand in 2024. The Company's principal activities consist of revenue from medical diagnosis products. The Company and its subsidiaries recognize revenue from when it satisfies a performance obligation and the recognition timing. Therefore, we considered this a key audit matter.

Our audit procedures include but are not limited to understanding the trading manners through walkthrough and to evaluating the appropriateness of the accounting policy related to revenue recognition from the sale of medical diagnosis products and the transactions made from sales by testing the internal control effectiveness determined by management. We confirm that the timing of recognizing revenue is when performance obligations are met by reviewing the terms of transaction. We confirm the correctness of recognizing revenue from sale of medical diagnosis product and the existence of sales revenue by performing transactions' detail testing which includes reviewing vouchers of selected samples and cash receipts record. We check transaction records to confirm the occurrence of the revenue. We perform cutoff testing through periods before and after the balance sheet date by reviewing related documentation of selected samples.

Please refer to Note 4 and 6. (15) for revenue related accounting policies and information.

Impairment of non-financial assets

As of December 31, 2024, the total net amount of property, plant and equipment, right-of-use assets and intangible assets of the Company and its subsidiaries was NT$149,241 thousand, accounted 22% of the consolidated total assets. The Company and its subsidiaries are engaged in medical diagnosis products research and development company. The Company and its subsidiaries are still at loss position in the year of 2024 because the medical products are still at development stage. As of the balance sheet date, the Company and its subsidiaries based on the external and internal sources to assess whether there is any indication of impairment. If there is indication of impairment, the impairment testing for above assets is required. The result of impairment evaluation is significant to the consolidated financial statements. Therefore, we consider impairment assessment as a key audit matter.

We have conducted audit procedures including but not limited to obtaining representation letter; to examing the evaluation of the Company and its subsidiaries made on possibility of impairment and its cash generating unit; to obtaining the information on assessing the recoverable amount and assumptions for the intangible assets regularly impairment with indefinite life. We also examined the historical and other business' financial information to evaluate whether the assumptions such as sales growth rate, gross margin, operating profit margin, and discount rate applied in the cash flow forecast are reasonable and are in conformity. We review the accuracy of the calculation for the amount recoverable. In Note 4 and 5 of consolidated financial statements to assess the appropriateness of the accounting policies and disclosures relating to the impairment of

non-financial assets.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Financial Reporting Standards, International Accounting Standards, Interpretations developed by the International Financial Reporting Interpretations Committee or the former Standing Interpretations Committee as endorsed by Financial Supervisory Commission of the Republic of China and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the ability to continue as a going concern of the Company and its subsidiaries, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company and its subsidiaries or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee or supervisors, are responsible for overseeing the financial reporting process of the Company and its subsidiaries.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or

the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company and its subsidiaries.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability to continue as a going concern of the Company and its subsidiaries. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company and its subsidiaries to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the accompanying notes, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company and its subsidiaries to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of 2024 consolidated financial statements and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse

consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Others

We have audited and expressed an unqualified opinion on the parent company only financial statements of the Company as of and for the years ended December 31, 2024 and 2023.

/s/Yu, Chien-Ju
/s/Chang, Chiao-Ying
Ernst & Young, Taiwan
February 25, 2025

Notice to Readers
The accompanying consolidated financial statements are intended only to present the consolidated financial position and results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

ASSETS	Notes	As of December 31, 2024	As of December 31, 2023
Current assets			
Cash and cash equivalents	4, 6	$17,756	$29,658
Financial assets at fair value through profit and loss, current	4, 6	4,000	5,000
Financial assets at amortized cost, current	4, 6, 8	343,950	252,610
Accounts receivable, net	4, 6	20,646	11,333
Accounts receivable-related parties, net	4, 6, 7	11	14
Current tax assets	4	7	-
Inventories	4, 6	30,094	25,022
Prepayments		1,282	2,073
Other current assets		339	183
Total current assets		418,085	325,893
Non-current assets			
Financial assets at fair value through other comprehensive income, non-current	4, 6	125,676	28,059
Property, plant and equipment	4, 6	72,181	68,429
Right-of-use assets	4, 6, 7	10,738	14,282
Intangible assets	4, 6	66,322	73,679
Refundable deposits	8	1,871	2,304
Total non-current assets		276,788	186,753
Total assets		$694,873	$512,646

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

LIABILITIES AND EQUITY	Notes	As of December 31, 2024	As of December 31, 2023
Current liabilities			
Contract liabilities, current	4, 6	$514	$2,054
Notes payable		-	113
Accounts payable		2,736	1,840
Other payables	6, 7	15,437	14,602
Provision, current	4, 6	935	1,129
Lease liabilities, current	4, 6, 7	5,147	4,397
Other current liabilities		374	284
Total current liabilities		25,143	24,419
Non-current liabilities			
Lease liabilities, non-current	4, 6, 7	5,724	9,991
Guarantee deposit received		288	288
Total non-current liabilities		6,012	10,279
Total liabilities		31,155	34,698
Equity attributable to the parent company			
Capital			
Common stock	4, 6	633,329	532,564
Capital collected in advance		-	742
Total capital		633,329	533,306
Capital surplus	4, 6	141,523	8,016
Retained earnings			
Accumulated deficits	6	(199,320)	(148,743)
Other components of equity			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income		(6,880)	(11,996)
Total equity attributable to the parent company		568,652	380,583
Non-controlling interests	6	95,066	97,365
Total equity		663,718	477,948
Total liabilities and equity		$694,873	$512,646

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

	Notes	For the Years Ended December 31, 2024	2023
Operating revenue	4, 6, 7	$53,105	$65,256
Operating costs	4, 6, 7	20,171	(24,232)
Gross profit		32,934	41,024
Operating expenses	4, 6, 7		
Sales and marketing expense		(19,704)	(20,894)
General and administrative expense		(34,111)	(29,993)
Research and development expense		(43,783)	(44,122)
Total operating expenses		(97,598)	(95,009)
Operating loss		(64,664)	(53,985)
Non-operating income and expenses			
Interest income	6	5,282	4,303
Other income	4, 6	6,830	6,729
Other gains and losses	4, 6	(144)	(73)
Financial costs	4, 6, 7	(180)	(123)
Total non-operating income and expenses		11,788	10,836
Net loss before income tax		(52,876)	(43,149)
Income tax expense	4, 6	-	-
Net loss		(52,876)	(43,149)
Other comprehensive income (loss)			
Items that will not be reclassified subsequently to profit or loss			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income	4, 6	5,116	(681)
Total other comprehensive income, net of tax		5,116	(681)
Total comprehensive loss		$(47,760)	$(43,830)
Net loss attributable to:			
Shareholders of the parent		$(50,577)	$(45,314)
Non-controlling interests		(2,299)	2,165
		$(52,876)	$(43,149)
Comprehensive loss attributable to:			
Shareholders of the parent		$(45,461)	$(45,995)
Non-controlling interests		(2,299)	2,165
		$(47,760)	$(43,830)
Loss per share-basic (in NT$)	6		
Loss per share-basic			
Net loss		$(0.88)	$(0.85)

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

	EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT							
				Retained earnings	Other components of equity			
	Common stock	Advance receipts for share capital	Capital surplus	Accumulated deficits	Unrealized gains or losses on financial assets measured at fair value through other comprehensive income (loss)	Total equity attributable to shareholders of the parent	Non-controlling interests	Total equity
Balance as of January 1, 2023	$532,214	$-	$95,738	$(192,055)	$(11,315)	$424,582	$95,200	$519,782
Accumulated deficit by capital surplus	-	-	(88,626)	88,626	-	-	-	-
Net loss for the year ended December 31, 2023	-	-	-	(45,314)	-	(45,314)	2,165	(43,149)
Other comprehensive income, net of tax for the year ended December 31, 2023	-	-	-	-	(681)	(681)	-	(681)
Total comprehensive income (loss)	-	-	-	(45,314)	(681)	(45,995)	2,165	(43,830)
Share-based payment transactions	350	742	904	-	-	1,996	-	1,996
Balance as of December 31, 2023	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583	$97,365	$477,948
Balance as of January 1, 2024	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583	$97,365	$477,948
Net loss for the year ended December 31, 2024	-	-	-	(50,577)	-	(50,577)	(2,299)	(52,876)
Other comprehensive income, net of tax for the year ended December 31, 2024	-	-	-	-	5,116	5,116	-	5,116
Total comprehensive income (loss)	-	-	-	(50,577)	5,116	(45,461)	(2,299)	(47,760)
Issue of shares	100,000	-	130,000	-	-	230,000	-	230,000
Share-based payment transactions	765	(742)	3,507	-	-	3,530	-	3,530
Balance as of December 31, 2024	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652	$95,066	$663,718

(The accompanying notes are an integral part of the consolidated financial statements.)

English Translations of Consolidated Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

	For the Years Ended December 31,	
	2024	2023
Cash flows from operating activities :		
Net loss before tax	$(52,876)	$(43,149)
Adjustments		
Depreciation	10,599	9,431
Amortization	7,684	8,034
Net loss on finacial assets at fair value through profit or loss	-	14
Interest expense	180	123
Interest revenue	(5,282)	(4,303)
Dividend income	(900)	(405)
Share-based payment	2,902	676
Loss on disposal of property, plant and equipment	188	169
Gain on disposal of investments	(29)	(15)
Gain on lease modification	-	(1)
Changes in operating assets and liabilities:		
Accounts receivable, net	(9,313)	(6,930)
Accounts receivable-related parties, net	3	89
Other receivables, net	18	44
Inventories, net	(11,610)	(5,410)
Prepayments	791	(1,049)
Other current assets	(174)	(42)
Contract liabilities	(1,540)	(612)
Notes payable	(113)	(71)
Accounts payable	896	962
Other payables	835	(3,490)
Provision	(194)	(217)
Other current liabilities	90	(32)
Cash outflow generated from operations	(57,845)	(46,184)
Interest received	5,282	4,303
Dividend received	900	405
Interest paid	(180)	(123)
Income tax paid	(7)	-
Net cash used in operating activities	(51,850)	(41,599)
Cash flows from investing activities :		
Acquisition Financial assets at fair value through other comprehensive income, non-current	(92,501)	-
Acquisition of financial assets measured at mortized cost	(294,390)	(23,910)
Proceeds from disposal of financial assets measured at amortized cost	203,050	52,080
Acquisition in financial assets at fair value through profit and loss, current	(63,700)	(5,000)
Proceeds from disposal of financial assets at fair value through profit and loss, current	64,729	3,016
Acquisition of property, plant and equipment	(2,722)	(293)
Decrease in refundable deposits	433	1,418
Acquisition of intangible assets	(327)	-
Net cash (used in) provided by investing activities	(185,428)	27,311
Cash flows from financing activities :		
Cash payment for the principal portion of the lease liabilities	(5,252)	(4,418)
Proceeds from issuing shares	230,000	-
Exercise of employee stock options	628	1,320
Net cash provided by (used in) financing activities	225,376	(3,098)
Net decrease in cash and cash equivalents	(11,902)	(17,386)
Cash and cash equivalents at beginning of period	29,658	47,044
Cash and cash equivalents at end of period	$17,756	$29,658

(The accompanying notes are an integral part of the consolidated financial statements.)

Independent Auditors' Report Translated from Chinese

To AmCad BioMed Corporation

Opinion

We have audited the accompanying parent company only balance sheets of AmCad BioMed Corporation (the "Company") as of December 31, 2024 and 2023, and the related parent company only statements of comprehensive income, changes in equity and cash flows for the years ended December 31, 2024 and 2023, and notes to the parent company only financial statements, including the summary of material accounting policies (together "the Parent company only financial statements").

In our opinion, the parent company only financial statements referred to above present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2024 and 2023, and their parent company only financial performance and cash flows for the years ended December 31, 2024 and 2023, in conformity with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the parent company only Financial Statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China (the "Norm"), and we have fulfilled our other ethical responsibilities in accordance with the Norm. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of 2024 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

The Company recognized operating revenue amounts to NT$ 11,704 thousand in 2024. The Company's principal activities consist of revenue from medical diagnosis products. The Company recognizes revenue from medical diagnosis products when it satisfies a performance obligation and the recognition timing. Therefore, we considered this a key audit matter.

Our audit procedures include but are not limited to understanding the trading manners through walkthrough and evaluating the appropriateness of the accounting policy related to revenue recognition from the sale of medical diagnosis products and the transactions made from sales by testing the internal control effectiveness determined by management. We confirm that the timing of recognizing revenue is when performance obligations are met by reviewing the terms of transaction. We confirm the correctness of recognizing revenue from sale of medical diagnosis products and the existence of sales revenue by performing transactions' detail testing which includes reviewing vouchers of selected samples and cash receipts record. We check transaction records to confirm the occurrence of the revenue. We perform cutoff testing through periods before and after the balance sheet date by reviewing related documentation of selected samples.

Please refer to Note 4 and 6. (14) for revenue related accounting policies and information.

Impairment of assets

As of December 31, 2024, the total net amount of investments accounted for under the equity method, property, plant and equipment, right-of-use assets and intangible assets of the Company was NT$184,905 thousand, accounted for 32 % of the total assets. The Company is engaged in medical diagnosis product research and development company. The Company is still at loss position in 2024 because the medical diagnosis products are still at development stage. As of the balance sheet date, the Company based on the external and internal sources to assess whether there is any indication of impairment. If there is indication of impairment, the impairment testing for above assets is required. The result of impairment evaluation is significant to the parent company only financial statements. Therefore, we consider impairment assessment as a key audit matter.

We have conducted audit procedures including but not limited to obtain representation letter; to examine the evaluation of the Company made on possibility of impairment and its cash generating unit; to obtain the information on assessing the recoverable amount and assumptions for the intangible assets regularly impairment with indefinite life. We also examined the historical and other business' financial information to evaluate whether the assumptions such as sales growth rate, gross margin, operating profit margin, and discount rate applied in the cash flow forecast are reasonable and are in conformity. We review the accuracy of the calculation for the amount recoverable. In Note 4 and 5 of parent company only financial statements to assess the appropriateness of the accounting policies and disclosures relating to the impairment of assets.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the requirements of the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the ability to continue as a going concern of the Company, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee or supervisors, are responsible for overseeing the financial reporting process of the Company.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability to continue as a going concern of the Company. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the accompanying notes, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the Company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of 2024 parent company only financial statements and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

/s/Yu, Chien-Ju
/s/Chang, Chiao-Ying
Ernst & Young, Taiwan
February 25, 2025

Notice to Readers
The accompanying parent company only financial statements are intended only to present the parent company only financial position and results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally accepted and applied in the Republic of China.

Accordingly, the accompanying parent company only financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY BALANCE SHEETS

December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

ASSETS	Notes	As of December 31, 2024	As of December 31, 2023
Current assets			
Cash and cash equivalents	4, 6	$7,898	$16,990
Financial assets at fair value through profit and loss, current	4, 6	4,000	5,000
Financial assets at amortized cost, current	4, 6, 8	255,370	155,060
Accounts receivable, net	4, 6	5,563	959
Accounts receivable-related parties, net	4, 6, 7	11	14
Current tax assets	4	7	-
Inventories	4, 6	4,878	3,454
Prepayments		1,186	1,613
Other current assets		321	165
Total current assets		279,234	183,255
Non-current assets			
Financial assets at fair value through other comprehensive income, non-current	4, 6	125,676	28,059
Investments accounted for under the equity method	4, 6	94,878	96,410
Property, plant and equipment	4, 6	67,285	65,065
Right-of-use assets	4, 6, 7	7,452	8,076
Intangible assets	4, 6	15,290	20,326
Refundable deposits	8	862	1,292
Total non-current assets		311,443	219,228
Total assets		$590,677	$402,483

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY BALANCE SHEETS

December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

LIABILITIES AND EQUITY	Notes	As of December 31, 2024	As of December 31, 2023
Current liabilities			
Contract liabilities, current	4, 6	$-	$1,501
Accounts payable		2,397	974
Other payables	6 ,7	11,445	10,759
Lease liabilities, current	4, 6, 7	2,175	1,453
Other current liabilities		370	280
Total current liabilities		16,387	14,967
Non-current liabilities			
Lease liabilities, non-current	4, 6, 7	5,350	6,645
Guarantee deposit received		288	288
Total non-current liabilities		5,638	6,933
Total liabilities		22,025	21,900
Equity			
Capital			
Common stock	4, 6	633,329	532,564
Capital collected in advance		-	742
Total capital		633,329	533,306
Capital surplus	4, 6	141,523	8,016
Retained earnings	6		
Accumulated deficits		(199,320)	(148,743)
Other components of equity			
Unrealized gains or losses on financial assets measured at fair value through other comprehensive income		(6,880)	(11,996)
Total equity		568,652	380,583
Total liabilities and equity		$590,677	$402,483

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

	Notes	For the Years Ended December 31, 2024	2023
Operating revenue	4, 6, 7	$11,704	$12,358
Operating costs	4, 6, 7	(4,398)	(4,777)
Gross profit		7,306	7,581
Operating expenses	4, 6, 7		
Sales and marketing expense		(13,527)	(14,238)
General and administrative expense		(26,784)	(23,083)
Research and development expense		(25,790)	(25,922)
Total operating expenses		(66,101)	(63,243)
Operating loss		(58,795)	(55,662)
Non-operating income and expenses			
Interest income	6	3,566	2,657
Other income	4, 6	6,556	6,379
Other gains and losses	4, 6	(236)	(80)
Financial costs	4, 6, 7	(136)	(51)
Share of profit or loss of subsidiary, associates and joint ventures accounted for using the equity method	4, 6	(1,532)	1,443
Total non-operating income and expenses		8,218	10,348
Net loss before income tax		(50,577)	(45,314)
Income tax expense	4, 6	-	-
Net loss		(50,577)	(45,314)
Other comprehensive income (loss)			
Items that will not be reclassified subsequently to profit or loss			
Unrealized gain or losses on financial assets at fair value through other comprehensive income	4, 6	5,116	(681)
Total other comprehensive income, net of tax		5,116	(681)
Total comprehensive loss		$(45,461)	$(45,995)
Earnings (loss) per share-basic (in NT$)			
Loss per share-basic	6		
Net loss		$(0.88)	$(0.85)

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

				Retained earnings	Other components of equity	
	Common stock	Advance receipts for share capital	Capital surplus	Accumulated deficits	Unrealized gains or losses on financial assets measured at fair value through other comprehensive income (loss)	Total equity
Balance as of January 1, 2023	$532,214	$-	$95,738	$(192,055)	$(11,315)	$424,582
Capital surplus for accumulated deficit	-	-	(88,626)	88,626	-	-
Net loss for the year ended December 31, 2023	-	-	-	(45,314)	-	(45,314)
Other comprehensive income, net of tax for the year ended December 31, 2023	-	-	-	-	(681)	(681)
Total comprehensive income (loss)	-	-	-	(45,314)	(681)	(45,995)
Share-based payment transactions	350	742	904	-	-	1,996
Balance as of December 31, 2023	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583
Balance as of January 1, 2024	$532,564	$742	$8,016	$(148,743)	$(11,996)	$380,583
Net loss for the year ended December 31, 2024	-	-	-	(50,577)	-	(50,577)
Other comprehensive income, net of tax for the year ended December 31, 2024	-	-	-	-	5,116	5,116
Total comprehensive income (loss)	-	-	-	(50,577)	5,116	(45,461)
Issue of shares	100,000	-	130,000	-	-	230,000
Share-based payment transactions	765	(742)	3,507	-	-	3,530
Balance as of December 31, 2024	$633,329	$-	$141,523	$(199,320)	$(6,880)	$568,652

(The accompanying notes are an integral part of the parent company only financial statements.)

English Translations of Financial Statements Originally Issued in Chinese

AMCAD BIOMED CORPORATION

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

	For the Years Ended December 31,	
	2024	2023
Cash flows from operating activities :		
Net loss before tax	$(50,577)	$(45,314)
Adjustments		
Depreciation	6,317	5,575
Amortization	5,036	5,583
Net gain on finacial assets at fair value through profit or loss	-	14
Interest expense	136	51
Interest revenue	(3,566)	(2,657)
Dividend income	(900)	(405)
Share-based payment	2,902	676
Share of loss of subsidiary, associates and joint ventures accounted for using the equity method	1,532	(1,443)
Loss on disposal of property, plant and equipment	188	150
Gain on disposal of investments	(29)	(15)
Gain on lease modification	-	(1)
Changes in operating assets and liabilities:		
Accounts receivable, net	(4,604)	(609)
Accounts receivable-related parties, net	3	89
Inventories, net	(5,240)	(1,198)
Prepayments	427	(908)
Other current assets	(156)	(43)
Contract liabilities	(1,501)	(184)
Accounts payable	1,423	773
Other payables	686	(2,482)
Other current liabilities	90	(33)
Cash outflow generated from operations	(47,833)	(42,381)
Interest received	3,566	2,657
Dividend received	900	405
Interest paid	(136)	(51)
Income tax paid	(7)	-
Net cash used in operating activities	(43,510)	(39,370)
Cash flows from investing activities :		
Acquisition Financial assets at fair value through other comprehensive income, non-current	(92,501)	-
Acquisition Financial assets at amortized cost	(254,390)	-
Proceed from redemption of financial assets measured at amortized cost	154,080	52,080
Acquisition in financial assets fair value through profit and loss, current	(63,700)	(5,000)
Proceeds from disposal of financial assets at fair value through profit and loss, current	64,729	3,016
Acquisition of property, plant and equipment	(2,550)	-
Increase in refundable deposits	430	(383)
Net cash (used in) provided by investing activities	(193,902)	49,713
Cash flows from financing activities :		
Cash payment for the principal portion of the lease liabilities	(2,308)	(1,501)
Proceeds from issuing shares	230,000	-
Exercise of employee stock options	628	1,320
Net cash provided by (used in) financing activities	228,320	(181)
Net (decrease) increase in cash and cash equivalents	(9,092)	10,162
Cash and cash equivalents at beginning of year	16,990	6,828
Cash and cash equivalents at end of year	$7,898	$16,990

(The accompanying notes are an integral part of the parent company only financial statements.)

Attachment E

AmCad BioMed Corporation
Articles of Incorporation
Comparison Table for the Amended Provisions

After amendment	Before amendment	Reason for amendment
Article 7 The Company may issue registered shares without printing physical share certificates; however, the shares shall be registered with a centralized securities depository. If physical share certificates are printed, they shall be issued only after being duly signed or stamped by the director(s) representing the Company, affixed with the Company seal, and certified in accordance with applicable laws. Employees who subscribe to new shares in accordance with Article 267 of the Company Act shall not transfer such shares within two years without the Company's consent; any transfer in violation of this provision shall be null and void.	Article 7 The Company may issue registered shares without printing physical share certificates; however, such shares shall be registered with a centralized securities depository. If physical share certificates are printed, they shall be issued only after being duly signed or stamped by at least three directors and affixed with the Company seal, and certified in accordance with applicable laws. Employees who subscribe to new shares in accordance with Article 267 of the Company Act shall not transfer such shares within two years without the Company's consent; any transfer in violation of this provision shall be null and void.	In accordance with the amendment to Article 162-2 of the Company Act.
Article 17 The Company shall have between nine and thirteen directors, of which no fewer than three shall be independent directors, and the number of independent directors shall not be less than one-fifth of the total number of directors. The number of directors to be elected shall be determined by a resolution of the Board of Directors. Directors shall be elected in accordance with the candidate nomination system stipulated in Article 192-1 of the Company Act, and shall be selected by the shareholders' meeting from the list of candidates. Each director shall serve a term of three years and may be re-elected. The nomination, election, and related procedures for directors shall be conducted in accordance with the Company Act and applicable regulations of the competent securities authority. The shareholding ratio of all directors shall comply with the "Rules and Review Procedures for Director and	Article 17 The Company shall have between nine and thirteen directors, of which no fewer than two shall be independent directors, and the number of independent directors shall not be less than one-fifth of the total number of directors. The number of directors to be elected shall be determined by a resolution of the Board of Directors. Directors shall be elected in accordance with the candidate nomination system stipulated in Article 192-1 of the Company Act, and shall be selected by the shareholders' meeting from the list of candidates. Each director shall serve a term of three years and may be re-elected. The nomination, election, and related procedures for directors shall be conducted in accordance with the Company Act and applicable regulations of the competent securities authority. The shareholding ratio of all directors shall comply with the "Rules and Review Procedures for Director and	In accordance with applicable regulations, the Company has established an Audit Committee composed entirely of independent directors, and the number of its members shall not be fewer than three.

After amendment	Before amendment	Reason for amendment
Supervisor Shareholding Ratios at Public Companies" as promulgated by the competent authority.	Supervisor Shareholding Ratios at Public Companies" as promulgated by the competent authority.	
Article 30 If the Company generates profit in a given fiscal year (profit is defined as pre-tax earnings before the deduction of employee compensation and director compensation), and after offsetting accumulated losses, if there remains a balance, no less than 3% and no more than 6% shall be allocated as employee compensation (of which no less than 20% shall be distributed to grassroots employees), and no more than 4% shall be allocated as director compensation. Such allocations shall be made pursuant to a resolution adopted by at least two-thirds of the directors present at a Board meeting attended by more than half of all directors. The aforementioned employee compensation and grassroots employee compensation may be distributed in the form of cash or shares, and may include employees of affiliated companies who meet certain criteria.	Article 30 If the Company generates profit in a given fiscal year (profit is defined as pre-tax earnings before the deduction of employee compensation and director compensation), and after offsetting accumulated losses, if there remains a balance, no less than 3% and no more than 6% shall be allocated as employee compensation, and no more than 4% shall be allocated as director compensation. Such allocations shall be made pursuant to a resolution adopted by at least two-thirds of the directors present at a Board meeting attended by more than half of all directors, and shall be reported to the shareholders' meeting. The aforementioned employee compensation may be distributed in the form of cash or shares, and may include employees of affiliated companies who meet certain criteria.	Pursuant to Article 14 of the Securities and Exchange Act, the Company shall specify a certain percentage of its annual earnings to be allocated as remuneration to grassroots employees.
Article 31 If the Company records earnings for the fiscal year, after paying all taxes and covering accumulated losses, it shall appropriate 10% of the remaining earnings as legal reserve in accordance with the law and make adjustments to the special reserve as required. Thereafter, the remaining balance, together with undistributed earnings from previous years, shall be allocated, with at least 10% to be distributed, based on a profit distribution proposal prepared by the Board of Directors and submitted to the shareholders' meeting for resolution. The Company's dividend policy shall be determined by the Board of Directors based on operational plans, investment projects, capital budget, and changes in internal and external conditions, and shall be distributed upon resolution of the shareholders' meeting.	Article 31 If the Company records earnings for the fiscal year, after paying all taxes and covering accumulated losses, it shall appropriate 10% of the remaining earnings as legal reserve in accordance with the law and make adjustments to the special reserve as required. Thereafter, the remaining balance, together with undistributed earnings from prior years, shall be allocated, with at least 50% to be distributed based on a profit distribution proposal prepared by the Board of Directors and submitted to the shareholders' meeting for resolution. The Company's dividend policy shall be determined by the Board of Directors based on operational plans, investment projects, capital budget, and changes in internal and external conditions, and shall be distributed upon resolution of the shareholders' meeting.	To reflect practical considerations, the percentage of stock dividends has been revised.

After amendment	Before amendment	Reason for amendment
The distribution of earnings shall be made in an appropriate proportion of cash dividends and stock dividends. If stock dividends are distributed, they shall account for at least 10% of the total dividends for the year. The actual allocation ratio may be adjusted based on the Company's cash flow, profitability, and the need for future business expansion.	In principle, the Company shall adopt a balanced dividend policy, with 50% of earnings distributed as cash dividends and 50% as stock dividends. The actual allocation ratio may be adjusted based on the Company's cash flow, profitability, and the need for future business expansion.	
Article 35 These Articles of Incorporation were established by resolution of the Founders' Meeting with the unanimous consent of all promoters on November 21, 2008, and shall take effect from the date of approval and registration by the competent authority. The first amendment was made on September 23, 2009. (Amendments in between omitted) The tenth amendment was made on May 18, 2023. The eleventh amendment was made on June 3, 2025.	Article 35 These Articles of Incorporation were established by resolution of the Founders' Meeting with the unanimous consent of all promoters on November 21, 2008, and shall take effect from the date of approval and registration by the competent authority. The first amendment was made on September 23, 2009. (Amendments in between omitted) The tenth amendment was made on May 18, 2023.	To include additional amendment numbers and dates.

IV. Appendix

Appendix A

AmCad BioMed Corporation
Rules of Procedure for Shareholders' Meetings

Article 1 (Basis for Formulation)

These Rules are established pursuant to Article 5 of the Corporate Governance Best-Practice Principles for TWSE/GTSM Listed Companies to establish a sound corporate governance system for the Company's shareholders' meetings, enhance oversight functions, and strengthen managerial efficiency.

Article 2

Unless otherwise provided by law or the Articles of Incorporation, the proceedings of the Company's shareholders' meetings shall be conducted in accordance with these Rules.

Article 3 (Convocation and Notice of Shareholders' Meetings)

Unless otherwise provided by law, the Company's shareholders' meetings shall be convened by the Board of Directors.

Any change in the method of convening the shareholders' meeting must be resolved by the Board of Directors and made no later than the date on which the meeting notice is issued.

The Company shall, at least 30 days before a regular shareholders' meeting or 15 days before an extraordinary shareholders' meeting, submit an electronic file containing the meeting notice, proxy form, and explanations of proposals including matters for acknowledgment, discussion, and election or dismissal of directors to the Market Observation Post System (MOPS).

The shareholders' meeting handbook and supplemental materials shall be submitted electronically to MOPS at least 21 days prior to a regular meeting or 15 days prior to an extraordinary meeting. No later than 15 days prior to the meeting, the Company shall prepare the physical copies of the handbook and supplemental materials, which shall be available for shareholders to consult at any time and shall be displayed at the Company and its shareholder services agent.

On the day of the shareholders' meeting, the handbook and supplemental materials shall be made available to shareholders as follows:

1.For physical meetings: provided at the venue.
2.For hybrid meetings: provided at the venue and uploaded electronically to the virtual meeting platform.
3.For virtual-only meetings: uploaded electronically to the virtual meeting platform.

Notices and announcements shall specify the purpose of the meeting; with the consent of the recipient, such notices may be delivered electronically.

If the meeting agenda includes the election or dismissal of directors, amendments to the Articles of Incorporation, capital reduction, application to terminate public listing, approval of director non-competition, capitalization of earnings or capital reserves, company dissolution,

merger, demerger, or matters under Article 185, Paragraph 1 of the Company Act; Article 26-1 and Article 43-6 of the Securities and Exchange Act; or Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Issuers, such matters must be itemized in the notice with explanations and may not be proposed as extraordinary motions.

Where the meeting notice specifies a full re-election of directors and includes the effective date of appointment, the same meeting shall not propose any change to the appointment date by extraordinary motion or any other means after the election.

Shareholders holding 1% or more of the total issued shares may submit one proposal for the regular shareholders' meeting. Proposals in excess of one shall not be included in the agenda.

If a shareholder proposal falls under any of the circumstances listed in Article 172-1, Paragraph 4 of the Company Act, the Board of Directors may exclude it from the agenda.

The Company shall, before the book closure date for the regular shareholders' meeting, announce the acceptance of shareholder proposals, the method (in writing or electronically), place, and period for submission, which shall not be fewer than ten days.

Shareholder proposals shall be limited to 300 words; proposals exceeding the limit will not be included in the agenda. Proposing shareholders must attend the meeting in person or by proxy and participate in the discussion of the proposal.

The Company shall notify shareholders of the results of their proposals prior to the issuance of the meeting notice. Proposals meeting the requirements of this Article shall be included in the agenda; those not included shall be explained by the Board of Directors during the meeting.

Article 4 (Proxy Attendance and Authorization)

A shareholder may issue a proxy using the form printed by the Company for each shareholders' meeting, specifying the scope of authorization and appointing a proxy to attend the meeting on their behalf.

Each shareholder may issue only one proxy form and appoint only one proxy. The proxy form must be delivered to the Company no later than five days before the date of the shareholders' meeting. In case of duplicate submissions, the one received first shall prevail, unless the shareholder explicitly states the revocation of a previous proxy.

If the proxy form has been delivered and the shareholder later wishes to attend the meeting in person or vote in writing or electronically, they must notify the Company in writing at least two days before the meeting to revoke the proxy. If the revocation is not made in time, the proxy shall remain valid and prevail.

If the shareholder intends to attend the meeting via video conferencing after submitting a proxy form, they must notify the Company in writing at least two days before the meeting to revoke the proxy. If not revoked within this period, the proxy's vote shall prevail.

Article 5 (Principles for Determining Meeting Location and Time)

The location for convening the shareholders' meeting shall be at the Company's registered office or at a location convenient for shareholders and suitable for holding the shareholders'

meeting. The meeting shall not begin earlier than 9:00 a.m. or later than 3:00 p.m. The determination of the meeting time and place shall take into full consideration the opinions of independent directors.

If the shareholders' meeting is held virtually, the restriction on physical location shall not apply.

Article 6 (Preparation of Sign-In Materials and Documents)

The meeting notice issued by the Company shall specify the time and place for shareholders, solicitors, and proxy agents (hereinafter collectively referred to as "shareholders") to check in, as well as other relevant instructions.

Check-in shall commence at least 30 minutes before the meeting starts. The check-in area must be clearly marked and staffed with adequate and competent personnel. For virtual meetings, shareholders shall check in via the virtual platform starting at least 30 minutes prior to the meeting; shareholders who complete check-in shall be deemed present in person.

Shareholders shall present attendance cards, sign-in cards, or other proof of identity. The Company shall not arbitrarily require additional documents beyond those specified. Solicitors of proxies must carry identification for verification.

Attending shareholders must submit their sign-in cards in place of signing.

The Company shall distribute the meeting handbook, annual report, attendance card, speech slip, ballots, and other meeting materials to shareholders present at the meeting. In the event of director elections, ballots shall also be provided.

If the shareholder is a government agency or a legal entity, multiple representatives may attend the meeting. If a legal entity is appointed as a proxy, it may designate only one representative to attend.

For virtual meetings, shareholders intending to attend by video must register with the Company at least two days before the meeting.

The Company shall upload the meeting handbook, annual report, and other related documents to the virtual meeting platform at least 30 minutes before the meeting and keep them accessible until the meeting ends.

Article 6-1

When the Company convenes a virtual shareholders' meeting, the meeting notice shall include the following information：

1. The method for shareholders to participate in the virtual meeting and exercise their rights.
2. Contingency measures in the event of natural disasters, incidents, or other force majeure that cause disruptions to the virtual meeting platform or participants, including at minimum：
   (1) The time frame during which the disruption must be resolved, and the date for postponement or continuation if necessary.
   (2) Shareholders who did not register for virtual participation in the original meeting may not attend the postponed or continued meeting.

(3) In hybrid meetings, if the virtual platform fails but a legal quorum is still present excluding virtual participants, the meeting shall continue. Shares represented virtually shall be counted toward the quorum, but such shareholders shall be deemed to have abstained from all proposals.

(4) Measures in the event that all proposals have been resolved but extraordinary motions have not yet been addressed.

3. In virtual-only meetings, appropriate alternative measures must be provided for shareholders who encounter difficulties with virtual participation.

Article 7 (Chairperson and Attendees)

If a shareholders' meeting is convened by the Board of Directors, the Chairperson of the Board shall preside. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If there is no Vice Chairperson or the Vice Chairperson is also unable to perform duties, the Chairperson shall designate an Executive Director as proxy. If there is no Executive Director, a Director shall be appointed. If the Chairperson does not appoint a proxy, the Executive Directors or Directors shall elect one among themselves.

For meetings convened by the Board, the Chairperson should preside in person. A majority of Directors should attend in person, and at least one member from each functional committee shall be present. Attendance shall be recorded in the meeting minutes.

If the meeting is convened by a convener other than the Board, the convener shall act as Chairperson. If there are multiple conveners, one shall be elected from among them.

The Company may appoint legal counsel, accountants, or relevant personnel to attend the meeting.

Article 8 (Audio/Video Recording of Meeting Process)

The entire proceedings of the shareholders' meeting shall be recorded by audio or video and kept for at least one year. If a shareholder files a lawsuit under Article 189 of the Company Act, the recording shall be kept until the conclusion of litigation.

For virtual meetings, the Company shall record and store data related to shareholder registration, check-in, questions, voting, and ballot counting results. The virtual meeting must be continuously recorded without interruption.

The aforementioned recordings and data must be properly preserved and provided to the entity responsible for managing the virtual meeting system.

Article 9 (Calculation of Shares Present and Commencement of Meeting)

Attendance at a shareholders' meeting shall be based on shares represented. Shares counted include those based on submitted sign-in cards, virtual platform check-ins, and voting rights exercised in writing or electronically.

At the scheduled meeting time, the Chairperson shall announce the start of the meeting and disclose the number of shares with and without voting rights. If shareholders representing more than

half of the total issued shares are not present, the Chairperson may postpone the meeting up to two times, not exceeding one hour in total. If a quorum of one-third is still not reached, the Chairperson shall declare the meeting adjourned. In virtual meetings, the Company shall announce the adjournment on the virtual platform.

If shareholders representing one-third of the total issued shares are present after the second delay, a tentative resolution may be passed per Article 175, Paragraph 1 of the Company Act, and a new meeting shall be convened within one month. Shareholders attending virtually must re-register in accordance with Article 6.

If the number of shares represented exceeds one-half of total issued shares before the end of the meeting, the Chairperson may re-submit the tentative resolution for voting under Article 174 of the Company Act.

Article 10 (Discussion of Proposals)

For meetings convened by the Board of Directors, the agenda shall be set by the Board. Each proposal, including amendments and extraordinary motions, shall be discussed and voted on one by one. The meeting shall proceed according to the predetermined agenda, and changes may only be made by resolution of the shareholders.

If the meeting is convened by someone other than the Board, the same rule applies.

Before the agenda (including extraordinary motions) has been fully discussed, the Chairperson shall not adjourn the meeting without resolution. If the Chairperson breaches procedure by prematurely adjourning the meeting, attending Directors shall assist shareholders in electing a new Chairperson by majority vote to continue the meeting.

The Chairperson shall ensure adequate explanation and discussion of all proposals and amendments. When discussion is deemed sufficient, the Chairperson may announce the end of discussion and proceed to vote, ensuring adequate time for voting is provided.

Article 11 (Shareholder Remarks)

Before speaking at the shareholders' meeting, attending shareholders shall complete a speech slip indicating the subject of the speech, shareholder account number (or attendance card number), and name. The Chairperson shall determine the order of speeches.

Shareholders who submit a speech slip but do not speak shall be deemed to have not spoken. If the speech content differs from that stated on the slip, the actual speech shall prevail.

Each shareholder may speak on the same proposal no more than twice and for no longer than five minutes per instance, unless otherwise approved by the Chairperson. The Chairperson may stop any shareholder who violates the rules or speaks off-topic.

During a shareholder's speech, other shareholders shall not speak or interrupt unless permitted by both the Chairperson and the speaker. The Chairperson shall stop any disruptions.

If a corporate shareholder appoints more than one representative to attend, only one representative may speak on any single proposal.

After a shareholder speaks, the Chairperson may respond personally or designate a relevant

person to respond.

For virtual meetings, shareholders participating online may submit questions in text form via the virtual platform after the Chairperson announces the opening of the meeting and until the announcement of adjournment. Each proposal may be questioned no more than twice, with a limit of 200 characters per question. These shareholders are not subject to the restrictions in the first to fifth paragraphs.

Article 12 (Calculation of Voting Rights and Recusal Requirements)

Voting at shareholders' meetings shall be calculated based on the number of shares held.

In making resolutions at shareholders' meetings, the shares of shareholders without voting rights shall not be included in the total number of issued shares.

Shareholders who have a conflict of interest with the Company on any proposal that may harm the Company's interests shall not vote nor exercise voting rights on behalf of others.

The shares of shareholders restricted from voting as described above shall not be counted in the number of voting rights represented by attending shareholders.

Unless the shareholder is a trust company or a shareholder services agent approved by the competent authority, any person receiving proxies from two or more shareholders shall not vote on behalf of shares exceeding 3% of the total voting rights of issued shares. Any excess shall not be counted.

Article 13 (Voting, Vote Counting, and Scrutineering Procedures)

Each share held by a shareholder entitles the shareholder to one vote, except for restricted shares or shares without voting rights as provided in Article 179, Paragraph 2 of the Company Act.

The Company shall allow shareholders to vote electronically and may also allow voting in writing. The methods of voting shall be specified in the meeting notice. Shareholders voting in writing or electronically shall be deemed to have attended in person but shall be considered to have abstained from voting on ad hoc motions or amendments to original proposals.

Shareholders who vote electronically or in writing shall ensure that their intent is received by the Company at least two days before the meeting. In case of duplicates, the earliest submission shall prevail unless a later submission explicitly revokes the earlier one.

If a shareholder has already voted electronically or in writing and wishes to attend in person or virtually, they must revoke their previous vote using the same method at least two days before the meeting. Failure to revoke in time means the original vote shall prevail. If a shareholder has also issued a proxy, the proxy vote shall prevail.

Unless otherwise provided by the Company Act or the Articles of Incorporation, proposals shall be passed by a majority of the voting rights represented at the meeting.

When voting, the Chairperson or a designated person shall announce the total number of voting rights represented, after which shareholders shall vote. The results of voting—approvals, rejections, and abstentions—shall be reported on the Market Observation Post System (MOPS) on the same day.

If a proposal has amendments or alternatives, the Chairperson shall determine the voting sequence. Once one version passes, all others shall be deemed rejected without further voting.

Vote scrutineers and counters shall be appointed by the Chairperson, but scrutineers must be shareholders.

Vote counting for resolutions or elections shall take place publicly at the meeting venue. Results, including vote counts, shall be announced immediately after counting and recorded.

For virtual meetings, shareholders shall vote via the virtual platform after the Chairperson announces the opening of the meeting and before the Chairperson announces the end of voting. Late votes shall be deemed abstentions.

In virtual meetings, vote counting shall be done once after the Chairperson announces the end of voting, and the results of resolutions and elections shall be announced.

For hybrid meetings, shareholders who registered for virtual attendance under Article 6 and wish to attend in person must cancel their virtual registration at least two days before the meeting via the same method; otherwise, they may only attend virtually.

Shareholders who voted in writing or electronically and have not revoked such votes but also attend the meeting virtually may not vote again, propose amendments, or vote on any amendments, except for ad hoc motions.

Article 14 (Election Matters)

When the shareholders' meeting includes the election of directors, it shall be conducted in accordance with the Company's relevant election rules, and the results, including the names of elected directors and their vote counts, shall be announced immediately.

Ballots from such elections shall be sealed and signed by scrutineers, properly preserved, and retained for at least one year. If a shareholder files a lawsuit under Article 189 of the Company Act, the ballots shall be retained until the conclusion of litigation.

Article 15 (Meeting Minutes and Signing Requirements)

Resolutions of shareholders' meetings shall be recorded in meeting minutes, signed or sealed by the Chairperson, and distributed to shareholders within 20 days after the meeting. The minutes may be produced and distributed electronically.

The Company may distribute the minutes by posting them on the Market Observation Post System (MOPS).

The meeting minutes shall include the year, month, and day of the meeting, the location, the Chairperson's name, the method of resolution, the essentials of the proceedings, and the voting results (including vote counts). In elections, the vote counts for each candidate shall be disclosed. The minutes shall be permanently retained during the Company's existence.

For virtual meetings, in addition to the above, the minutes shall include the start and end times, meeting format, names of the Chairperson and minute taker, and any contingency handling in case of disruptions to the virtual meeting platform or participation due to force majeure.

If the Company convenes a virtual-only meeting, the minutes shall also record the alternative

measures provided for shareholders who experience difficulties with virtual participation.

Article 16 (Public Announcements)

On the day of the meeting, the Company shall prepare a summary table showing the number of shares solicited by solicitors, represented by proxies, and represented by shareholders voting in writing or electronically, and display it clearly at the venue. For virtual meetings, this data shall be uploaded to the virtual meeting platform at least 30 minutes before the meeting and remain accessible until the meeting ends.

For virtual meetings, the total number of shares represented shall be disclosed on the platform at the time the meeting is called to order. If updated during the meeting, such updates shall also be disclosed.

If the resolutions passed involve material information under relevant laws or TPEx regulations, the Company shall disclose such information on MOPS within the prescribed timeframe.

Article 17 (Maintenance of Order at the Venue)

Meeting personnel shall wear identification badges or armbands.

The Chairperson may instruct marshals or security personnel to help maintain order. Marshals or security personnel assisting at the venue shall wear armbands or badges labeled "Marshal."

If the venue is equipped with a sound system, shareholders may only use Company-provided equipment to speak. The Chairperson may stop those who violate this rule.

If a shareholder violates the rules of procedure, disobeys the Chairperson’s instructions, and disrupts the meeting, the Chairperson may instruct marshals or security personnel to remove the individual.

Article 18 (Recess and Continuation of the Meeting)

During the meeting, the Chairperson may announce a recess at an appropriate time. If force majeure occurs, the Chairperson may temporarily suspend the meeting and announce a time to resume.

If the meeting venue becomes unavailable before the agenda (including extraordinary motions) is completed, the meeting may be relocated by resolution of the shareholders.

The shareholders’ meeting may also be postponed or continued within five days by resolution pursuant to Article 182 of the Company Act.

Article 19

For virtual shareholders’ meetings, the Company shall disclose the results of all voting and elections on the virtual platform immediately after the end of voting.

Article 20

When convening a virtual shareholders’ meeting, the Chairperson and the minute taker shall be at the same physical location within the territory of the Republic of China. The Chairperson shall

announce the address of that location at the start of the meeting.

Article 21

For virtual shareholders' meetings, the Chairperson shall announce at the beginning of the meeting that, except in cases where continuation or postponement is not required as specified under Paragraph 4, Article 44-20 of the Regulations Governing the Administration of Shareholder Services of Public Companies, if force majeure causes disruptions to the virtual meeting platform or participation for more than 30 minutes before the meeting is adjourned, the meeting shall be postponed or continued within five days. This shall not be subject to Article 182 of the Company Act.

Shareholders who did not register for virtual participation in the original meeting shall not attend the postponed or continued meeting.

For shareholders who registered for virtual participation and completed check-in but do not attend the continued or postponed meeting, their attendance, voting rights, and election rights from the original meeting shall be included in the counts for the postponed or continued meeting.

When a meeting is postponed or continued in accordance with the first paragraph, items for which voting and counting have been completed and results announced, including director elections, do not need to be discussed or resolved again.

In the case of a hybrid meeting, if the virtual platform becomes nonfunctional as described in the first paragraph but a legal quorum is still present excluding the virtual participants, the meeting shall continue. The shares represented by virtual participants shall be counted in the quorum, but their votes shall be deemed abstentions on all proposals.

Article 22

When the Company convenes a virtual shareholders' meeting, it shall provide appropriate alternative measures for shareholders who experience difficulty participating virtually.

Article 23

These Rules shall take effect upon approval by the shareholders' meeting. Amendments shall be subject to the same procedure.

These Rules of Procedure were established on December 8, 2010. The first amendment was made on April 12, 2013. The second amendment was made on June 27, 2014. The third amendment was made on May 22, 2020. The fourth amendment was made on May 18, 2023.

Appendix B

AmCad BioMed Corporation
Articles of Incorporation

Chapter I－General Provisions

Article 1 The Company is organized in accordance with the Company Act and is named "安克生醫股份有限公司" in Chinese and "AmCad BioMed Corporation" in English.

Article 2 The Company shall engage in the following business activities:

1、 CE01010 General Instrument Manufacturing

2、 CE01030 Optical Instrument Manufacturing

3、 CE01990 Other Optical and Precision Instruments Manufacturing

4、 CZ99990 Other Unclassified Industrial Product Manufacturing

5、 E605010 Computer Equipment Installation Services

6、 F108031 Wholesale of Medical Devices

7、 F113030 Wholesale of Precision Instruments

8、 F208031 Retail Sale of Medical Devices

9、 F213040 Retail Sale of Precision Instruments

10、F213990 Retail Sale of Other Machinery and Equipment

11、F218010 Retail Sale of Information Software

12、F401010 International Trade

13、F601010 Intellectual Property Rights Services

14、I103060 Management Consulting Services

15、I199990 Other Consulting Services

16、I301010 Information Software Services

17、I301020 Data Processing Services

18、I301030 Electronic Information Supply Services

19、IG01010 Biotechnology Services

20、IG02010 Research and Development Services

21、IZ99990 Other Business Services

22、J399010 Software Publishing

23、CF01011 Medical Device Manufacturing

24、ZZ99999 All business activities not prohibited or restricted by laws and regulations, except those requiring special approval.

Article 3 The Company's head office is located in Taipei City. Branch offices may be established

domestically or internationally upon a resolution of the Board of Directors and approval by the competent authority, if required.

Article 4 The method of public announcement by the Company shall be conducted in accordance with Article 28 of the Company Act.

Chapter II – Shares

Article 5 The total authorized capital of the Company shall be NT$1,000,000,000, divided into 100,000,000 shares, each with a par value of NT$10. Of these, 3,000,000 shares shall be reserved for the issuance of employee stock options. The Board of Directors is authorized to issue the shares in installments as necessary.

Article 5-1 The Company may, with the approval of shareholders representing more than half of the total issued shares and by a resolution passed by at least two-thirds of the voting rights of shareholders present, transfer repurchased shares to employees at a price lower than the average repurchase price, or issue employee stock options at a subscription price lower than the closing price on the issuance date.

Article 6 The Company may provide external guarantees and may invest as a shareholder with limited liability in other companies. The total amount of such investments may exceed 40% of the Company's paid-in capital.

Article 7 The Company's registered shares may be issued without printing physical share certificates, but they shall be registered with the centralized securities depository. If printed, the share certificates shall be signed or sealed by at least three directors and bear the Company's official seal, and shall be issued in accordance with the law. Shares subscribed by employees in accordance with Article 267 of the Company Act may not be transferred within two years without Company approval; otherwise, such transfers shall be null and void.

Article 8 All matters relating to shareholder services shall be handled in accordance with the Company Act and the "Regulations Governing the Administration of Shareholder Services of Public Companies" as promulgated by the competent authority.

Article 9 The Company shall suspend the transfer of shares for a period of 60 days before the annual shareholders' meeting, 30 days before an extraordinary shareholders' meeting, or 5 days prior to the record date for distribution of dividends, bonuses, or other benefits.

Chapter III – Shareholders' Meetings

Article 10 The shareholders' meetings of the Company are classified into two types：

1.Annual Shareholders' Meeting：convened once a year by the Board of Directors in

accordance with the law within six months after the end of each fiscal year.

2.Extraordinary Shareholders' Meeting: convened by the Board of Directors as necessary in accordance with the law.

Shareholders' meetings may be held via video conferencing or other methods announced by the central competent authority.

Article 11 The Chairperson of the Board shall preside over the shareholders' meeting. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If both the Chairperson and Vice Chairperson are on leave or unable to perform duties, the Chairperson shall designate a Director to act as proxy. If no proxy is designated, the Directors shall elect one among themselves to act as Chairperson.

Article 12 Notice of an annual shareholders' meeting shall be given to all shareholders at least 30 days in advance; notice of an extraordinary shareholders' meeting shall be given at least 15 days in advance.

If the recipient consents, the notice may be given electronically.

Article 13 A shareholder who is unable to attend a shareholders' meeting may issue a proxy form printed by the Company, specifying the scope of authorization and appointing a proxy to attend the meeting. The method of proxy attendance shall be handled in accordance with Article 177 of the Company Act and the "Regulations Governing the Use of Proxies for Attendance at Shareholders' Meetings of Public Companies" issued by the competent authority.

Article 14 Unless otherwise provided or restricted by laws and regulations, each share of the Company shall carry one voting right.

Article 15 Except where otherwise provided by laws and regulations, a resolution of the shareholders' meeting shall be adopted by shareholders representing more than half of the total issued shares being present in person or by proxy, and approved by a majority of the voting rights represented at the meeting.

Article 16 Resolutions of the shareholders' meeting shall be recorded in minutes, signed or sealed by the Chairperson of the meeting, and distributed to shareholders within twenty days after the meeting.

The distribution of the minutes shall be conducted in accordance with Article 183 of the Company Act.

Chapter IV – Directors, Board of Directors, and Managers

Article 17 The Company shall have 9 to 13 Directors, including no fewer than 2 Independent Directors and at least one-fifth of the total number of Directors. The number of Directors to be elected shall be resolved by the Board of Directors. Directors shall be

elected using a candidate nomination system in accordance with Article 192-1 of the Company Act, and selected from the list of candidates at the shareholders' meeting. Each Director shall serve a term of three years and may be re-elected.

The nomination, election, and related matters for Directors shall be handled in accordance with the Company Act and relevant regulations of the competent securities authority.

The shareholding ratio of all Directors shall comply with the "Regulations Governing Minimum Number of Shares Held by Directors and Supervisors of Public Companies" as prescribed by the competent authority.

Article 18 In accordance with Article 14-4 of the Securities and Exchange Act, the Company shall establish an Audit Committee composed entirely of Independent Directors. The Audit Committee or its members shall exercise the powers of Supervisors as provided under the Company Act, the Securities and Exchange Act, and other applicable laws and regulations.

Article 18-1 In accordance with Article 14-6 of the Securities and Exchange Act, the Company shall establish a Remuneration Committee. The Committee or its members shall perform duties in accordance with the "Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of Companies Whose Stock is Listed on the Stock Exchange or Traded Over the Counter."

Article 19 If the number of Directors falls short by one-third or all Independent Directors are dismissed, the Board of Directors shall convene a shareholders' meeting within 60 days to hold a by-election. The newly elected Directors shall serve only for the remainder of the original term.

Article 20 The Board of Directors shall be composed of all Directors and shall have the following powers:

1.Preparing business plans.

2.Proposing distribution of earnings or coverage of losses.

3.Proposing capital increases or decreases.

4.Establishing important bylaws and organizational rules.

5.Appointing and dismissing the Company's managerial officers.

6.Establishing or abolishing branch offices.

7.Preparing budgets and final accounts.

8.Other powers granted under the Company Act or by resolutions of the shareholders' meeting.

Article 21 The Board of Directors shall elect a Chairperson and a Vice Chairperson from among

themselves by a majority vote of at least two-thirds of the Directors present at a meeting attended by a majority of all Directors. The Chairperson shall represent the Company externally and may, for business needs, designate a Director to act on behalf of the Chairperson in the office.

Article 22 Except as otherwise provided by the Company Act, meetings of the Board of Directors shall be convened by the Chairperson. Resolutions of the Board shall, unless otherwise required by the Company Act, be adopted by a majority of the Directors present at a meeting attended by a majority of the Directors.

Article 23 Notice of a Board meeting shall state the purpose of the meeting and be given to each Director at least seven days in advance. In urgent circumstances, meetings may be convened at any time.
Notice may be given in writing, by fax, or electronically.

Article 24 The Chairperson of the Board shall preside over Board meetings. If the Chairperson is on leave or otherwise unable to perform duties, the Vice Chairperson shall act as proxy. If both are unable to perform duties, the Chairperson shall designate a Director to act as proxy. The Chairperson may also designate a Director to act on their behalf at the office for business purposes. If no proxy is designated, the Directors shall elect one among themselves.

Directors shall attend Board meetings in person. If unable to attend, a Director may appoint another Director as proxy. However, a proxy may only act for one other Director per meeting.

Board meetings may be conducted via video conferencing. Directors participating by video shall be deemed present in person.

Article 25 The remuneration of all Directors shall be determined by the Board of Directors and may be paid at prevailing industry standards regardless of Company profit or loss. The Company may purchase liability insurance for Directors during their term of office to cover duties performed on behalf of the Company.

Article 26 The Company may appoint managerial officers. Their appointment, dismissal, and remuneration shall be handled in accordance with Article 29 of the Company Act. The Company may purchase liability insurance for managerial officers for duties performed within the scope of their responsibilities.

Chapter V – Accounting

Article 27 The Company's fiscal year shall begin on January 1 and end on December 31 of each year. The Company shall conduct year-end closing procedures accordingly.

Article 28 At the end of each fiscal year, the Board of Directors shall prepare：(1) the business

report,(2) the financial statements, and (3) proposals for profit distribution or loss compensation,which shall be submitted to the annual shareholders' meeting for approval in accordance with the law.

Article 29 Dividends and bonuses shall be distributed to shareholders in proportion to the number of shares held. No dividends or bonuses shall be distributed when there is no profit.

Article 30 If the Company generates profit in a given fiscal year (profit is defined as pre-tax earnings before deduction of employee compensation and directors' remuneration), after making up for accumulated losses, the Company shall allocate 3% to 6% of the remaining amount as employee compensation and no more than 4% as directors' remuneration. The distribution shall be resolved by the Board of Directors with the attendance of at least two-thirds of the Directors and the consent of more than half of those present, and reported to the shareholders' meeting.

Employee compensation mentioned above may be paid in the form of cash or stock and may be granted to employees of the Company's qualified subsidiaries.

Article 31 If the Company generates earnings upon final accounting for the year, after paying all taxes and making up for past losses, it shall appropriate 10% as legal reserve and make adjustments to the special reserve as required by law. The remaining surplus, along with undistributed earnings from previous years, shall be allocated—at least 50% of which shall be proposed by the Board of Directors as a profit distribution plan and submitted to the shareholders' meeting for approval.

The Company's dividend policy shall be determined by the Board of Directors based on operational plans, investment projects, capital budgets, and internal and external environmental changes, and shall be distributed upon approval by the shareholders' meeting. In principle, the Company adopts a balanced dividend policy, aiming to distribute 50% of dividends in cash and 50% in stock, with adjustments based on cash flow, earnings status, and future operational expansion needs.

Article 32 Shareholders entitled to receive dividends and bonuses must be those listed in the shareholders' register five days prior to the record date for such distributions.

Chapter VI – Supplementary Provisions

Article 33 The Company's organizational rules and administrative guidelines shall be established separately.

Article 34 Any matters not provided for in these Articles of Incorporation shall be handled in accordance with the provisions of the Company Act.

Article 35 These Articles of Incorporation were established and agreed upon by all promoters at the promoters' meeting on November 21, 2008, and shall take effect upon approval and

registration by the competent authority. The first amendment was made on September 23, 2009. The second amendment was made on December 8, 2010. The third amendment was made on May 6, 2011. The fourth amendment was made on October 19, 2012. The fifth amendment was made on April 12, 2013. The sixth amendment was made on June 27, 2014. The seventh amendment was made on May 27, 2015. The eighth amendment was made on May 24, 2016. The ninth amendment was made on June 7, 2017. The tenth amendment was made on May 18, 2023.

Appendix C

AmCad BioMed Corporation
Shareholding Status of Directors

1. A breakdown of the number of shares held by directors：

April 5, 2025 (Book closure date)

Job title	Name	Number of shares registered in the register of shareholders	Remark
Chairman	Lee Yi-Li	582,327	
Vice Chairman	Phytohealth Corp.	22,155,049	Representative：Lee I-Lin
Director	Phytohealth Corp.	22,155,049	Representative：Lee Chen-Chia
Director	Chang King-Jen	2,902,000	
Director	Maywufa Company Ltd.	3,994,996	Representative：Sheu Jin-Chuan
Director	Phytohealth Corp.	22,155,049	Representative：Chen Wal-ter
Director	Jen Yu Ltd.	46,000	Representative：Chiou Shu-Ti
Director	Maywufa Company Ltd.	3,994,996	Representative：Wang Tsay-Ping
Director	Jen Yu Ltd.	46,000	Representative：Gary T. Tseng
Independent Director	Chang Ching-Tian	0	
Independent Director	Huang Weng-Foung	0	
Independent Director	Li Hsueh-Yu	0	
Independent Director	Lin She-Yi	0	

2. The minimum number of shares held by all directors and the detailed list of the number of shares held by the shareholder register：

April 5, 2025 (Book closure date)

Job title	Number of shares to be held	Number of shares registered in theregister of shareholders
Director	5,066,632	29,680,372

Remarks：

(1)The Company’s paid-in capital is NT$633,329,000, divided into 63,332,900 shares.

(2)The Company has appointed more than two Independent Directors. In accordance with Article 2 of the “Regulations Governing Minimum Number of Shares Held by Directors and Supervisors of Public Companies and the Verification Thereof,” the minimum shareholding requirement for all Directors is reduced to 80% of the originally prescribed ratio.

(3)Independent Directors are excluded from the calculation of Directors’ shareholdings.